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0. Summary 
Title 
 
Japanese POEMS syndrome with Thalidomide (J-POST) Trial: multicenter, 
randomized, double-blind, placebo-controlled, parallel-group, and long-term safety 
trial of Thalidomide for POEMS syndrome 
Objectives 1) To evaluate the efficacy and safety of thalidomide compared to a placebo in 
POEMS syndrome. 2) To evaluate the safety and efficacy of long-term 
administration of thalidomide. 
Design A multicenter, randomized, placebo-controlled, double-blind, parallel group, 
comparative trial (randomized controlled trial [RCT] period) followed by a 
long-term safety evaluation trial (long-term open trial period). 
Phase Phase II/III trial 
Active Product 
FPF300 
Generic name: thalidomide (code number: FPF 300) 
Dosage form: Size 2 hard capsule containing 100 mg of thalidomide 
Comparator 
FPF300 Placebo 
Placebo capsule visually indistinguishable from the active product and containing 
no thalidomide 
Inclusion Criteria (1) POEMS syndrome diagnosed according to published diagnostic criteria as 
‘Probable’ and ‘Definite’ 
Definite: Three major criteria and at least one minor criterion. 
Probable: Two major criteria (peripheral neuropathy (polyneuropathy) and 
elevated serum vascular endothelial growth factor (VEGF)), and at least one 
minor criterion. 
Possible: Only one major criterion (peripheral neuropathy (polyneuropathy)), and 
at least two minor criteria. 
Major criteria: polyneuropathy (necessary criterion)  
elevated serum VEGF level (≥1000 pg/mL) 
M protein (blood M protein-positive). 
Minor criteria: sclerotic bone lesions, Castleman disease, organomegaly, oedema, 
pleural effusion, ascites, hydropericardium, endocrinopathy (adrenal, thyroid, 
pituitary, gonadal, parathyroid, and pancreatic), skin changes (hyperpigmentation, 
hypertrichosis, plethora, hemangiomata, cyanosis, or white nails), papilledema, 
and thrombocytosis. 
*Because of the high prevalence of diabetes mellitus and thyroid abnormalities, this 
diagnosis alone is not sufficient to meet this minor criterion. 
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(2) Age ≥ 20 years at the time of providing informed consent. 
(3) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of ≤ 3. 
(4) Overall neuropathy limitation scale (ONLS) total score of ≤ 9. 
(5) Any of the following laboratory abnormalities: 
AST (GOT) / ALT (GPT) ≤ 4.0 × upper limit of normal, creatinine < 1.5 × upper 
limit of normal. 
(6) Hospitalization at the start of the randomized comparative study period and the 
long-term safety period. 
(7) Regular clinic visits every 4 weeks. 
(8) No clinically significant electrocardiogram (ECG) abnormalities and the absence 
of advanced bradycardia or bradycardia requiring medical treatment. 
(9) Written, informed consent from the patient or legal representative. 
(10) Ineligible for high-dose chemotherapy with peripheral blood stem cell 
transplantation during the study period. 
(11) Informed consent to thalidomide education and risk management system. 
Exclusion criteria (1) Use of thalidomide, melphalan, bortezomib, or lenalidomide within 24 weeks of 
providing consent. 
(2) Unstable patients. 
(3) Oral or intravenous use of steroids within 4 weeks of providing informed 
consent. 
(4) Women who are pregnant, may be pregnant, wish to become pregnant, or are 
breastfeeding. Men who want their partners to become pregnant. 
(5) Serious complications (heart failure, renal failure, liver failure, peptic ulcer with 
bleeding, ileus, poorly controlled diabetes, etc.). 
(6) Other comorbid malignant tumors. 
(7) Known allergy to thalidomide or dexamethasone. 
(8) Serious mental disorder. 
(9) Use of any other experimental drug or therapy within 12 weeks of providing 
informed consent. 
(10) Use of prohibited drugs (other than β-blockers) or therapy within 4 weeks of 
the baseline. 
(11) Patients deemed unsuitable for the trial by the principal investigator or 
sub-investigator for any other reason. 
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Endpoints [Randomized comparative study period] 
Primary endpoint: 
[Efficacy] Serum VEGF reduction rate at 24 weeks. 
 
Secondary endpoints: 
(1) Secondary efficacy endpoints: 
Serum VEGF level 
Reaching target serum VEGF level (1000 pg/mL) 
Motor function (manual muscle testing, grip strength, and ONLS) 
Median/ulnar nerve conduction velocity, compound muscle action potential 
amplitude, and F wave latency 
M protein qualitative test (blood test and immunofixation) 
Pleural effusion size 
Vital capacity (VC) 
Body weight 
QOL (SF-36). 
 
(2) Secondary safety endpoint: 
Adverse events. 
 
[Long-term open trial period] 
Primary endpoint: 
[Safety] Adverse events. 
 
Secondary endpoints: 
[Efficacy] 
Serum VEGF level 
Reaching target serum VEGF level (1000 pg/mL) 
Motor function (manual muscle testing, grip strength, and ONLS) 
Median/ulnar nerve conduction velocity, compound muscle action potential 
amplitude, and F wave latency 
M protein qualitative test (blood test and immunofixation) 
Pleural effusion size 
Vital capacity (VC) 
4/92
 - 5 - 
 
Body weight 
QOL (SF-36). 
Methods 
[Randomized 
comparative study 
period] 
 
(1) Administration schedule 
The first day of study drug administration is defined as day 1, and the first day of 
each subsequent cycle is also defined as day 1. 
The length of a cycle is set at 28 days (4 weeks), and a total of 6 cycles (24 weeks) 
will be conducted; however, at the conclusion of study drug administration (after 24 
weeks), administration will be permitted until the day before testing and 
observation. 
Dexamethasone (Decadron tablets, 0.5 mg) will be administered concomitantly with 
the study drug a total of 4 times from day 2 to day 5; however, if dexamethasone 
cannot be administered on day 2 for unavoidable reasons, its administration should 
be started by Day 4 at the latest. 
Patients will be hospitalized at the beginning of study drug administration and will 
remain in the hospital, in principle, for ≥3 weeks. 
 
(2) Dosage and administration method 
One capsule of the study drug will be administered once per day before bedtime 
every other day. 
Starting on Day 8, the dose will be increased in accordance with the dose escalation 
criteria. 
Dexamethasone (Decadron tablets, 0.5 mg) will be administered at a dose of 12 
mg/m2 once per day (maximum dose 20 mg/day, decimals to be rounded off) after 
breakfast for 4 days during each cycle  
 
<Dose escalation criteria> 
After day 7, if the absence of skin abnormalities and hematological toxicity 
(reduced neutrophil count and/or reduced platelet count) of Grade 3 or higher has 
been confirmed, the study drug dosage will be increased from one capsule every 
other day to one capsule every day. 
After day 14, if the absence of skin abnormalities and hematological toxicity 
(reduced neutrophil count and/or reduced platelet count) of Grade 3 or higher has 
been confirmed, the study drug dosage will be increased from one capsule every 
day to two capsules every day. The administration period for each dose is set at ≥7 
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days and the final dose escalation should be completed within 28 days. 
 
<Dose maintenance criteria> 
Following the completion of dose escalation, if the absence of skin abnormalities 
and hematological toxicity (reduced neutrophil count and/or reduced platelet count) 
of Grade 3 or higher has been confirmed, the study drug dosing regimen of two 
capsules every day will be maintained. 
 
<Dose reduction criteria> 
If skin abnormalities or hematological toxicity (reduced neutrophil count and/or 
reduced platelet count) of Grade 3 or higher occur, the dose must be reduced by one 
dose level. Dose reductions due to other adverse events will be determined based on 
the assessment of the principal investigator or sub-investigator. 
 
<Re-administration/Reincrease criteria> 
Reincrease, following suspension or dose reduction due to adverse events, should 
follow the administration method, dose escalation criteria, and maintenance criteria 
described above. In the event of a reincrease following a reduction due to adverse 
events, the dose reincrease should be to the dose being administered before the 
reduction. The administration period for each dose is ≥7 days; no period is set for 
the completion of a dose increase. Re-administration of the drug following a 
suspension should begin with the same dose as from before the suspension.  
 
<ECG monitoring (during hospitalization)> 
(1) Prior to study drug administration 
Prior to study drug administration, ECG monitoring is performed for at least 24 
hours to confirm the absence of clinically relevant or serious findings. 
(2) After study drug administration 
During study drug administration, ECG monitoring is performed for 3 weeks, in 
principle, to confirm the absence of clinically relevant or serious findings. 
 
<Termination criteria> 
The principal investigator or sub-investigator will terminate the trial when one of 
the following criteria is met. 
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(1) When adverse events occur even when the dose level has been reduced to the 
minimum level in accordance with the dose reduction criteria and when termination 
is deemed necessary by the principal investigator or sub-investigator. 
(2) When adverse events occur making the continuation of study drug 
administration difficult and termination is deemed necessary by the principal 
investigator or sub-investigator. In the event of subacute exacerbation during the 
randomized comparative study period, administration should not be terminated and 
the patient should be transitioned into the long-term, open trial period. 
(3) When a patient requests his/her withdrawal from the study. 
(4) When study drug administration is deemed unsuitable by the principal 
investigator or sub-investigator. 
(5) When termination of the study drug is deemed necessary by the principal 
investigator or sub-investigator. 
(6) When a patient is found to be pregnant. 
(7) When continued enrollment in the study is deemed impossible for any other 
reason by the principal investigator or sub-investigator. 
Other than in case (3), the day of termination is not the day the adverse event 
resulting in termination occurred, but the day that the principal investigator or 
sub-investigator decided that termination was necessary. 
 
<Criteria for early transition from the randomized comparative study period 
to the long-term open trial period> 
In the event of subacute exacerbation of the primary disease during the random 
comparative study period, the patient should be transitioned early to the long-term 
open trial period. Determination of subacute exacerbation of the primary disease is 
conducted by the principal investigator or sub-investigator. 
 
<Definition of subacute exacerbation of the primary disease> 
When clinical symptoms are exacerbated, a chest X-ray and other tests are 
performed as deemed necessary. Subacute exacerbation is determined to have 
occurred if either of the following is observed and if subacute exacerbation is 
deemed present by the principal investigator or sub-investigator. 
(1) Increase of ONLS total score of ≥2 compared to the beginning of the RCT 
period, or ≥1 level exacerbation of pleural effusion size. 
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*Pleural effusion size: Assessed with a chest X-ray in a sitting or standing position. 
Computed tomography is also used as deemed necessary. 
Small……..Accumulation of up to 1/4 of the pulmonary field 
Moderate…Accumulation of up to 1/3 of the pulmonary field 
Large……..Accumulation of up to 1/2 of the pulmonary field 
(2) Body weight increase of 5 kg/month 
Increase in body weight of ≥5 kg in less than 1 month. Measured at any visit at the 
discretion of the principal investigator or sub-investigator. 
 
<Criteria for transition from RCT period to long-term open trial period> 
Patients who have completed the RCT period or who have met the criteria for early 
transition from RCT will move on to the long-term open trial period. Transition to 
the long-term open trial period should be conducted within 6 weeks after the 
completion of the RCT period. 
Prior to the start of the long-term open trial period, the principal investigator or 
sub-investigator must explain this part of the study to the patient in simple terms 
using a consent/explanation form approved by the Institutional Review Board 
(IRB), and obtain the patient’s voluntary written consent to participate in the trial. 
 
<Concomitant drugs and therapies from the start of the RCT period to the end 
of the long-term open trial period> 
Dexamethasone will be administered concomitantly with the study drug a total of 4 
times from day 2 to day 5 as described in the protocol; however, if dexamethasone 
cannot be administered on day 2 for unavoidable reasons, its administration should 
be started by Day 4 at the latest. Dexamethasone will be administered using 
commercially available 0.5mg Decadron tablets and its information will be obtained 
from the most recent package insert. However, during the long-term open trial 
period the dosage forms of dexamethasone are not specified. 
 
<Prohibited drugs and therapies from the start of the RCT period to the end of 
the long-term open trial period> 
(1) Antitumor therapy: 
Chemotherapy, hormone therapy, immunotherapy, antibody therapy, and 
radiotherapy. 
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(2) Other study drugs used for an antitumor effect 
(3) Steroid therapy (oral, injection), except for dexamethasone in the long-term 
open trial period 
(4) Thalidomide, melphalan, bortezomib, and lenalidomide 
(5) β-blockers 
Methods 
[Long-term open 
trial period] 
(1) Administration schedule 
The first day of study drug administration is defined as day 1, and the first day of 
each subsequent cycle is also defined as day 1. 
The length of a cycle is set at 28 days (4 weeks), and a total of 12 cycles (48 weeks) 
will be conducted; however, at the conclusion of study drug administration (after 
48weeks), administration will be permitted until the day before testing and 
observation. 
Patients will be hospitalized at the start of study drug administration and will 
generally remain hospitalized for more than 3 weeks. 
 
(2) Dosage and administration method 
One capsule (100 mg) of the study drug will be administered once per day before 
bedtime every other day. 
Starting on Day 8, the dose will be increased in accordance with the dose escalation 
criteria. 
 
<Dose escalation criteria> 
After day 7, if the absence of skin abnormalities and hematological toxicity 
(reduced neutrophil count and/or reduced platelet count) of Grade 3 or higher has 
been confirmed, the study drug dosage will be increased from one capsule every 
other day to one capsule every day. 
After day 14, if the absence of skin abnormalities and hematological toxicity 
(reduced neutrophil count and/or reduced platelet count) of Grade 3 or higher has 
been confirmed, the study drug dosage will be increased from one capsule every 
day to two capsules every day. The administration period for each dose is set at ≥7 
days and the final dose escalation should be completed within 28 days. 
 
<Dose maintenance criteria> 
Following the completion of dose escalation, if the absence of skin abnormalities 
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and hematological toxicity (reduced neutrophil count and/or reduced platelet count) 
of Grade 3 or higher has been confirmed, the study drug dosing regimen of two 
capsules every day will be maintained. 
 
< Dose escalation criteria of thalidomide and dexamethasone concomitant 
usage criteria after dose maintenance  > 
In the event of subacute exacerbation of the primary disease; 
The study drug dosage will be increased to three capsules every day. If subacute 
exacerbation still persists, in spite of this dose escalation, dexamethasone can also 
be administered concomitantly. As long as safety can be confirmed, the timing of 
the initial dose of dexamethasone is not specified. 
 
<Dexamethasone dosage and administration method> 
Dexamethasone should be administered at a dose of 12 mg/m2 once per day either 
orally or intravenously after breakfast for 4 days (maximum dose 20 mg/day; 
calculated based on the patient’s body weight at the initial dexamethasone 
administration for the long-term open trial period, decimals to be rounded off). The 
timing of the initial dosing of dexamethasone is not specified. In principle, 
following the initial dose, dexamethasone should be administered from day 2 to day 
5 of the specified 28-day (4-week) study drug administration cycle; however, as 
long as safety can be confirmed via the assessment of the principal investigator or 
sub-investigator, it is possible for the administration timing to be changed. 
 
<Thalidomide dose escalation criteria and dexamethasone concomitant usage 
criteria after early transition from RCT to long-term open trial  > 
In principle, the dosage, administration method, and administration schedule of the 
study drug in the long-term open trial should be followed as described in 6.6.1 and 
6.6.2. However, when patients meet the early transition criteria (a sudden increase 
in disease activity and the exacerbation of symptoms), the principal investigator or 
sub-investigator can, with due consideration of the patient’s safety, decide to shorten 
the administration period of each dosing level as well as complete dose escalation 
early in order to reach the maintenance level. Furthermore, on the determination of 
the principal investigator or sub-investigator upon due consideration of the patient’s 
safety, the study drug dose can be increased to the maximum of three capsules (300 
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mg) and dexamethasone can be concomitantly administered as necessary. 
 
<Dose reduction criteria> 
If skin abnormalities or hematological toxicity (reduced neutrophil count and/or 
reduced platelet count) of Grade 3 or higher occur, the dose must be reduced by one 
dose level. Dose reductions due to other adverse events will be determined based on 
the assessment of the principal investigator or sub-investigator. 
 
<Res-administration/Reincrease criteria> 
Reincrease, following suspension or dose reduction due to adverse events, should 
follow the administration method, dose escalation criteria, and maintenance criteria 
described above. In the event of a reincrease following a reduction due to adverse 
events, the dose reincrease should be to the dose being administered before the 
reduction. The administration period for each dose is ≥7 days; no period is set for 
the completion of a dose increase. Re-administration of the drug following a 
suspension should begin with the same dose as from before the suspension. 
 
<ECG monitoring (during hospitalization)> 
(1) Prior to study drug administration 
Prior to study drug administration, ECG monitoring is performed for at least 24 
hours to confirm the absence of clinically relevant or serious findings. 
(2) After study drug administration 
During study drug administration, ECG monitoring is performed for 3 weeks, in 
principle, to confirm the absence of clinically relevant or serious findings. 
 
<Termination criteria> 
The principal investigator or sub-investigator will terminate the trial when one of 
the following criteria is met. 
(1) When adverse events occur even when the dose level has been reduced to the 
minimum level in accordance with the dose reduction criteria and when termination 
is deemed necessary by the principal investigator or sub-investigator. 
(2) When adverse events occur making the continuation of study drug 
administration difficult and termination is deemed necessary by the principal 
investigator or sub-investigator. In the event of subacute exacerbation during the 
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randomized comparative study period, administration should not be terminated and 
the patient should be transitioned into the long-term, open trial period. 
(3) When a patient requests his/her withdrawal from the study. 
(4) When study drug administration is deemed unsuitable by the principal 
investigator or sub-investigator. 
(5) When termination of the study drug is deemed necessary by the principal 
investigator or sub-investigator. 
(6) When a patient is found to be pregnant. 
(7) When continued enrollment in the study is deemed impossible for any other 
reason by the principal investigator or sub-investigator. 
Other than in case (3), the day of termination is not the day the adverse event 
resulting in termination occurred, but the day that the principal investigator or 
sub-investigator decided that termination was necessary. 
 
Target number of 
patients 
24 (12 per group) 
Trial period Trial period: 5 years (September/01/2010–August/31/2015) 
Registration period: 3.5 years (September/01/2010–February/28/2014) 
Ethics and GCP The study will be conducted in adherence to ethical principles based on the 
Declaration of Helsinki, as well as Good Clinical Practice (GCP) and related 
regulatory requirements. 
Institutional 
Review Board 
Prior to the start of the study, the IRB of each trial site will evaluate the ethical, 
scientific, and medical appropriateness of the study. The study is conducted after 
obtaining approval from the IRB. In the event that the IRB return evaluation results 
of “approved with modification,” the study will be conducted after the protocol, 
case report form, and consent/explanation forms etc. are modified, based on the 
evaluation results. In addition, the IRB will continuously review whether the study 
is being appropriately conducted at least once per year. 
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Explanation and written consent 
FPF300 administration group 
FPF300 
1–2 capsules once per day before 
bedtime 
Dexamethasone (decadron 0.5 mg tablet) 
12 mg/m2 (maximum dose: 20 mg/day) 
Once per day after breakfast for 4 days 
   
Registration and random assignment  
(Assignment adjustment factors: serum VEGF level and the 
presence/absence of pleural effusion) 
R
C
T period 
 
Long-term
 open trial period 
 
Trial concluded 
FPF300 
1–2 capsules once per day before bedtime 
 
Upon subacute exacerbation: 
 (1) FPF300, 3 capsules once per day before bedtime 
(2) Dexamethasone, 12 mg/m2 (maximum dose: 20 
mg/day). Once per day after breakfast for 4 days 
once per cycle 
 
 
FPF300 placebo group 
FPF300 placebo 
1–2 capsules once per day before bedtime 
Dexamethasone (decadron 0.5 mg tablet) 
12 mg/m2 (maximum dose: 20 mg/day) 
Once per day after breakfast for 4 days 
once per cycle 
≤28 days 
24 weeks 
48 weeks 
Screening 
Post-obser vation 
4 weeks 
Post-observation 
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Abbreviations and Definitions of Terms 
Abbreviation Definition 
ACTH Adrenocorticotropic hormone 
AST (GOT) Aspartate aminotransferase (Glutamic oxaloacetic transaminase) 
ALT (GPT) Alanine aminotransferase (Glutamic pyruvic transaminase) 
APTT Activated partial thromboplastin time 
BUN Blood urea nitrogen 
Ch-E Cholinesterase 
CPK Creatine phosphokinase 
CRP C-reactive protein 
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
FDP Fibrin/fibrinogen degradation products 
FSH Follicle stimulating hormone 
FT3 Free triiodothyronine 
FT4 Free thyroxine 
γ-GTP γ-Glutamyltranspeptidase 
HGH Human growth hormone 
LDH Lactate dehydrogenase 
LH Luteinizing hormone 
ONLS Overall neuropathy limitation scale 
PBSCT Peripheral blood stem cell transplantation 
PT Prothrombin time 
PS (ECOG) Performance status (Eastern Cooperative Oncology Group) 
QOL Quality of life  
TSH Thyroid stimulating hormone 
VC Vital capacity 
VEGF Vascular endothelial growth factor 
Drug management assistant 
An individual close to the patient or a health care professional chosen 
to assist in managing drugs for the patient, preventing of the ingestion 
of the drugs by other people, and confirming  the return of all unused 
drugs. 
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Criteria and terms used in the study 
 
Diagnostic criteria 
The study applies the following diagnostic criteria for Crow-Fukase syndrome5, 8. 
 
Definite:  Meeting all three major criteria and at least one minor criterion. 
Probable:  Meeting peripheral neuropathy (polyneuropathy) and elevated serum VEGF among the 
major criteria and at least one minor criterion. 
Possible:  Meeting peripheral neuropathy (polyneuropathy) among the major criteria, and at least 
two minor criteria. 
 
Major criteria:   polyneuropathy (necessary criterion)  
Elevated serum VEGF level (≥1000 pg/mL) 
M protein (blood M protein-positive). 
Minor criteria:  sclerotic bone lesions, Castleman disease, organomegaly, oedema, pleural effusion, 
ascites, hydropericardium, endocrinopathy (adrenal, thyroid, pituitary, gonadal, 
parathyroid, and pancreatic), skin changes (hyperpigmentation, hypertrichosis, plethora, 
hemangiomata, cyanosis, or white nails), papilledema, and thrombocytosis. 
*Because of the high prevalence of diabetes mellitus and thyroid abnormalities, this diagnosis alone is not 
sufficient to meet this minor criterion. 
 
 
Study change criteria 
The following terms are used with regard to study change criteria. 
Postponement: Delay of the trial or of study drug administration. 
Suspension Temporary halting of study drug administration during the study. Said dose may be 
re-administered later . The period of suspension should be within 2 weeks.. 
Termination Termination of study drug administration in the middle of the study. Said dose will not 
be re-administered later. 
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1. Introduction 
1.1 Background of the target disease 
Crow-Fukase syndrome, which is related to multiple myeloma, is a disease that presents with various 
specific clinical symptoms such as polyneuropathy associated with plasmacytoma, organomegaly, 
endocrinopathy, M protein (monoclonal gammopathy), hyperpigmentation, vibrissae, and edema. It is also 
known as POEMS syndrome, an acronym formed by the first letters of the primary symptoms of 
polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin change. Although 
many details regarding the pathological mechanism of these diverse symptoms remain unknown, the 
proliferation of plasma cells and the associated overproduction of vascular endothelial growth factor 
(VEGF) are presumed to play a central role. This is indicated by the particularly strong correlation between 
serum VEGF level and the disease status1-4. 
The number of patients affected by the disease is extremely small. In a Japanese nationwide study 
conducted in 2003, the number of patients in Japan was estimated to be approximately 340, most of whom 
developed the disease in late–middle age to old age5. In addition, because most reports of Crow-Fukase 
syndrome have originated in Japan, the prevalence has been inferred to be higher in Japan than in the 
West23-24. The prognosis is known to be relatively poor due to respiratory failure as a result of pleural 
effusion and respiratory muscle paralysis, as well as multiple organ failure, primarily renal failure6-7. 
 
1.2 Standard of care for the target disease 
International therapeutic guidelines for Crow-Fukase syndrome have been published in a Cochrane 
Database Systematic Review8 based on a joint study by the Mayo Clinic in the United States, Kagoshima 
University, and Chiba University. However, because the disease is rare, there have been no randomized, 
parallel group comparative studies; consequently, guidelines have been based on case reports and studies 
with small numbers of patients. Thus, a standard therapy with established efficacy does not currently exist. 
In the 1980s, it was not understood that Crow-Fukase syndrome was caused by plasma cell abnormalities, 
and so the primary therapy was steroid therapy. Steroid therapy has a fixed short-term effect due to its 
inhibition of glucocorticoid receptor-mediated VEGF production. However, it is incapable of inhibiting 
disease progression in the medium-to-long term, and the mean survival period is only 28 months7. The 
pathology of Crow-Fukase syndrome was later understood to be neoplastic proliferation of plasma cells. 
Therefore, as with multiple myeloma (which is also a neoplastic disease of plasma cells), 
melphalan-prednisolone therapy became the first-line treatment for Crow-Fukase syndrome. 
Melphalan-prednisolone therapy has been the most commonly utilized therapy since the 1990s due to its 
relative safety and its suitability for most patients. The median survival period with 
melphalan-prednisolone therapy is 5 to 7 years, demonstrating a certain improvement in prognosis7. 
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However, this therapy presents a number of problems, such as an increased risk of myelodysplastic 
syndrome and other second primary cancers when the total dose of melphalan exceeds 1,100 mg, cases 
where the treatment is ineffective, and cases of recurrence of Crow-Fukase syndrome 5 years after 
treatment and onward9-11, 20. 
Starting in approximately the year 2000, similarly to multiple myeloma, high-dose chemotherapy with 
autologous peripheral blood stem cell transplantation has been reported as a treatment of Crow-Fukase 
syndrome. This therapy has garnered an extremely high level of attention as a novel therapy. It elicits 
dramatic improvements in therapeutic outcomes, namely a 1-year serum VEGF normalization rate of 100% 
and a 2-year remission rate of 94 to 100%11-13. However, transplantation therapy involves a risk of 
treatment-related death and is unsuitable for many patients due to reasons such as advanced age and other 
complications. 
Based on the above, high-dose chemotherapy with autologous peripheral blood stem cell therapy is 
currently considered the first-line treatment for Crow-Fukase syndrome due to its marked effects. However, 
this therapy is unsuitable for a number of patients and it cannot be performed at all facilities. For patients 
who cannot undergo this therapy, melphalan-prednisolone therapy is the most commonly-selected option. 
However, as stated previously, the indication of recurrence and the risk of second primary cancers due to 
alkylating agents are major problems that cannot be ignored. Therefore, the establishment of a therapeutic 
option other than melphalan-prednisolone therapy for Japanese patients who cannot undergo transplantation 
therapy is an urgent concern. 
 
1.3 Background of the study 
1.3.1 Thalidomide (Fujimoto Pharmaceutical Corporation, brand name: Thaled Capsule 100) 
Thalidomide is a glutamate derivative that was created by Ciba (now Novartis Pharma AG) in 1953. In 
former West Germany, Chemie Grunenthal discovered that thalidomide possesses an analgesic effect. It 
went on sale as a sleep-inducing and mood-stabilizing agent in 1957 and was subsequently made 
commercially available in 46 countries, although not in the United States. In Japan, clinical development of 
thalidomide was conducted by Dainippon Pharmaceutical Co., Ltd. (now Sumitomo Dainippon Pharma Co., 
Ltd.), who received permission in 1957 to produce thalidomide as a therapeutic agent for insomnia and 
other conditions. Thalidomide went on sale in Japan in 1958 under the brand name Isomin. In 1960, an oral 
medication with a composition including thalidomide (brand name: Proban-M, etc.) was sold as a 
therapeutic agent for gastric hyperacidity, gastritis, and peptic ulcers. However, when taken while pregnant, 
thalidomide was found to result in limb malformation and other severe birth defects as well as stillbirths, 
leading to immediate recalls and cancellation of sales in Europe. In Japan, however, recalls and 
cancellation of sales were delayed, leading to a large-scale drug disaster which resulted in the birth of 
21/92
 - 22 - 
 
approximately 1,000 so-called “thalidomide babies” (only 309 of which were officially recognized)20, 26. 
Despite these events, research into the pharmacological effects of thalidomide continued even after 
approval for its production as a pharmaceutical agent was revoked. In 1965, an Israeli physician reported 
that thalidomide inhibits erythema leprosum nodosum15. Since then, based on its various pharmacological 
effects, such as antiangiogenesis and inhibition of tumor necrosis factor alpha, thalidomide has been 
researched in numerous clinical studies for its effects in conditions such as autoimmune diseases and 
malignant tumors27. The efficacy of thalidomide in multiple myeloma was first demonstrated in 1999 and 
thalidomide currently maintains its position as an important therapeutic agent in the treatment of this 
disease. 
In Japan, the production and sale of thalidomide as a therapeutic agent for recurrent and refractory 
multiple myeloma was approved in 2008. However, because the use of thalidomide by women during 
pregnancy results in severe fetal teratogenicity of the upper limbs, sense organs, and cardiovascular system, 
products containing thalidomide require strict safety controls. Currently, for multiple myeloma treatment, 
thalidomide product safety controls consist of a procedure called TERMS® (Thalidomide Education and 
Risk Management System). The crucial components of TERMS® are information provision, education, 
registration, central management, and assessment regarding thalidomide. Thalidomide is prescribed based 
on this system. 
 
1.3.2 Therapeutic effects and trial outcomes of thalidomide in the target disease 
Crow-Fukase syndrome is related to multiple myeloma and is anticipated to be affected by 
thalidomide17-18. Furthermore, the reported pharmacological actions of thalidomide include not only various 
antitumor effects such as antiangiogenesis, inhibition of cytoadhesin expression, apoptosis induction, and 
cell growth inhibition, but also the inhibition of VEGF production27, and as such, thalidomide may be 
particularly effective for Crow-Fukase syndrome. 
There are two case reports of the efficacy of thalidomide therapy in severe cases of Crow-Fukase 
syndrome in which transplantation therapy was unsuitable, one in 200418 and one in 200617. Based on these 
reports, the Neurology Department of Chiba University Hospital began conducting an open trial 
investigating the efficacy of thalidomide therapy for Crow-Fukase syndrome as an investigator initiated 
trial in 2006. In 2008, intermediate results of the therapeutic outcomes of thalidomide administration for 
nine patients with Crow-Fukase syndrome for whom transplantation therapy was unsuitable or whose 
systemic condition was poor were reported; the 1-year remission rate was 56%, and the 2-year survival rate 
was 100%19. Although the long-term effects of thalidomide therapy in Crow-Fukase syndrome are 
unknown, its efficacy for multiple myeloma has been established, and it poses no risk of primary second 
cancers. Also, in comparison to melphalan, thalidomide results in a lower frequency of myelosuppression 
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and other side effects, does not require dose adjustment in patients with decreased renal function (a 
common complication), and can be used relatively safely. Furthermore, in patients who cannot undergo 
transplantation therapy due to serious organ dysfunction, transplantation therapy may become possible if 
the treatment improves organ dysfunction; however, the effect of melphalan-prednisolone therapy on bone 
marrow reduces the subsequent harvest efficiency of autologous peripheral blood stem cells. On the other 
hand, thalidomide does not pose such a risk, leaving sufficient potential for future transplantation therapy. 
 
1.3.3 Background of the present clinical trial plan 
Thalidomide has been indicated as a potential substitute for melphalan-prednisolone therapy in patients 
with Crow-Fukase syndrome who cannot undergo transplantation therapy17-19. Unfortunately, case reports 
and single-center open trials with small numbers of patients are not sufficient for establishing the efficacy 
of thalidomide. Crow-Fukase syndrome is more prevalent in Japan than in the West and, as such, there are 
strong calls for the urgent implementation of multicenter, randomized, parallel-group comparative studies 
and for Japan to deliver evidence-based therapeutic guidelines to the world. Based on the above, we drafted 
a plan for a multicenter, randomized, placebo-controlled, double-blind, parallel-group study with the 
objective of demonstrating the efficacy of thalidomide against Crow-Fukase syndrome with a high level of 
evidence. 
One of the largest problems in medical treatment for Crow-Fukase syndrome is the absence of standard 
therapeutic guidelines, which results in widely differing treatment depending on the medical facility. 
Although thalidomide is likely effective in Crow-Fukase syndrome, its current use depends on the 
individual physician’s directions and their personal imports. As the efficacy of thalidomide is established 
and its indications are expanded, it may begin to be provided as a standard therapy to all patients, 
regardless of the individual medical facility. In addition, due to its history of harm, thalidomide must be 
used under a strict management system; the current situation in which thalidomide is ordered privately from 
abroad is not desirable. However, a clinical trial for a disease this rare cannot be expected to come from 
industry, but must be done as an investigator-initiated trial for a new indication. 
 
2. Objectives 
1) To evaluate the efficacy and safety of thalidomide in Crow-Fukase syndrome compared to a placebo. 
2) To evaluate the safety and efficacy of long-term administration of thalidomide. 
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2.1 Randomized controlled trial (RCT) period 
2.1.1 Primary endpoint: 
[Efficacy] 
Serum VEGF reduction rate at 24 weeks. 
 
2.1.2 Secondary endpoints: 
[Efficacy] 
Serum VEGF level 
Reaching target serum VEGF level (1000 pg/mL) 
Motor function (manual muscle testing, grip strength, and ONLS) 
Median/ulnar nerve conduction velocity, compound muscle action potential amplitude, and F wave 
latency 
M protein qualitative test (blood test and immunofixation) 
Pleural effusion size 
Vital capacity (VC) 
Body weight 
QOL (SF-36). 
 
[Safety] 
Adverse events. 
 
2.2 Long-term open trial period 
2.2.1 Primary endpoint: 
[Safety] 
Adverse events. 
 
2.2.2 Secondary endpoints: 
[Efficacy] 
Serum VEGF level 
Reaching target serum VEGF level (1000 pg/mL) 
Motor function (manual muscle testing, grip strength, and ONLS) 
Median/ulnar nerve conduction velocity, compound muscle action potential amplitude, and F wave 
latency 
M protein qualitative test (blood test and immunofixation) 
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Pleural effusion size 
Vital capacity (VC) 
Body weight 
QOL (SF-36). 
25/92
 - 26 - 
 
3. Study Design 
A multicenter, randomized, placebo-controlled, double-blind, parallel group, comparative trial (RCT 
period) followed by a long-term safety evaluation trial (long-term open trial period). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Explanation and written consent 
 
FPF300 administration group 
FPF300 
1–2 capsules once per day before bed 
Dexamethasone (decadron 0.5 mg tablet) 
12 mg/m2 (maximum dose: 20 mg/day) 
Once per day after breakfast for 4 days 
once per cycle 
 
Registration and random assignment  
(Assignment adjustment factors: serum VEGF level, 
presence/absence of pleural effusion) 
 
R
C
T period 
 
Long-term
 open trial period 
 
FPF300 
1–2 capsules once per day before bed 
 
Upon subacute exacerbation 
 (1) FPF300: 3 capsules once per day before bed 
(2) Dexamethasone: 12 mg/m2 (maximum 
dose: 20 mg/day). Once per day after breakfast 
for 4 days once per cycle 
 
 
FPF300 placebo group 
FPF300 placebo 
1–2 capsules once per day before bed 
Dexamethasone (decadron 0.5 mg tablet) 
12 mg/m2 (maximum dose: 20 mg/day) 
Once per day after breakfast for 4 days 
once per cycle 
≤28 days 
 
24 weeks 
 
48 weeks 
 
Screening 
 
Post-obser vation 
 4 weeks 
 
Post-observation 
 
Trial concluded 
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3.1 Target number of subjects and study (trial) period  
Target number of subjects: 24 patients (12 patients per group) 
Study (trial) period: 5 years (September/01/2010–August/31/2015) 
Case registration (patient enrollment) period: 3.5 years (September/01/2010–February/28/2014) 
 
4. Eligibility and registration of study subjects  
Patients who meet all of the inclusion criteria below and do not fall under any of the exclusion criteria will 
be included in this trial.  
 
4.1 Inclusion criteria 
(1) POEMS syndrome diagnosed according to published diagnostic criteria as ‘Probable’ and ‘Definite’ 
Definite: Three major criteria and at least one minor criterion. 
Probable: Two major criteria (peripheral neuropathy (polyneuropathy) and elevated serum vascular 
endothelial growth factor (VEGF)), and at least one minor criterion. 
Possible: Only one major criteria (peripheral neuropathy (polyneuropathy)), and at least two minor 
criteria. 
 
Major criteria: polyneuropathy (necessary criterion)  
elevated serum VEGF level (≥1000 pg/mL) 
M protein (blood M protein-positive). 
Minor criteria: sclerotic bone lesions, Castleman disease, organomegaly, oedema, pleural effusion, 
ascites, hydropericardium, endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, and 
pancreatic), skin changes (hyperpigmentation, hypertrichosis, plethora, hemangiomata, cyanosis, or 
white nails), papilledema, and thrombocytosis. 
*Because of the high prevalence of diabetes mellitus and thyroid abnormalities, this diagnosis alone is not 
sufficient to meet this minor criterion. 
 
(2) Age ≥ 20 years at the time of providing informed consent. 
(3) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of ≤ 3. 
(4) Overall neuropathy limitation scale (ONLS) total score of ≤ 9. 
(5) Any of the following laboratory abnormalities: 
AST (GOT) / ALT (GPT) ≤ 4.0 × upper limit of normal, creatinine < 1.5 × upper limit of normal. 
(6) Hospitalization at the start of the randomized comparative study period and the long-term safety period. 
(7) Regular clinic visits every 4 weeks. 
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(8) No clinically significant electrocardiogram (ECG) abnormalities and the absence of advanced 
bradycardia or bradycardia requiring medical treatment. 
(9) Written, informed consent from the patient or legal representative. 
(10) Ineligible for high-dose chemotherapy with peripheral blood stem cell transplantation during the study 
period. 
(11) Informed consent to thalidomide education and risk management system.  
 
Rationale 
(1). Created on the basis of diagnostic criteria 5, 8.  
(2). Although there are no age limitations specified in the guidelines for clinical evaluation methods of 
antineoplastic agents, for the treatment of diseases with a poor prognosis such as the one being investigated 
in this study, it is necessary to inform the patient of the diagnosis, and so therefore the age limit was set to 
include competent individuals age 20 years and older.  
(3 and 4). To exclude cases with a high probability of exacerbation of the primary disease during the study 
period, participation was limited to patients with a good status showing a PS 0-3 and ONLS score of 9 or 
less.  
(5 and 8). Based on the package insert for thalidomide and the standards used in other anticancer drug 
clinical trials, this criteria was set to ensure the safety of the study subjects.  
(8). Two adverse events of sinus arrest occurred during this study and this criteria was established later in 
order to ensure the safety of the study subjects. 
(6). Established because in-hospital testing was required to safely begin administration of the study drug.  
(7). Established to ensure that the subjects selected were those who could successfully complete the study. 
(9). Established so as to implement the study in accordance with ethical principles such as those outlined 
in the Helsinki Declaration.  
(10). Established because patients who are eligible for high-dose chemotherapy accompanied by peripheral 
blood stem cell transplantation might experience a delay in the start of their transplantation treatment 
because of their participation in this study.  
(11). Commercial versions of the study drug must conform to the thalidomide product safety management 
procedures, and so it was determined that consent regarding Safety Management is also essential in this 
study.  
  
4.2 Exclusion criteria 
(1) Use of thalidomide, melphalan, bortezomib, or lenalidomide within 24 weeks of providing consent. 
(2) Unstable patients. 
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(3) Oral or intravenous use of steroids within 4 weeks of providing informed consent. 
(4) Women who are pregnant, may be pregnant, wish to become pregnant, or are breastfeeding. Men who 
want their partners to become pregnant. 
(5) Serious complications (heart failure, renal failure, liver failure, peptic ulcer with bleeding, ileus, poorly 
controlled diabetes, etc.). 
(6) Other comorbid malignant tumors. 
(7) Known allergy to thalidomide or dexamethasone. 
(8) Serious mental disorder. 
(9) Use of any other experimental drug or therapy within 12 weeks of providing informed consent. 
(10) Use of prohibited drugs (other than β-blockers) or therapy within 4 weeks of the baseline. 
(11) Patients deemed unsuitable for the trial by the principal investigator or sub-investigator for any other 
reason. 
  
Rationale of Settings 
(1-3), (5), (6), and (8-11): Established because any of these conditions could have an influence on the 
evaluations in this study.  
(4 and 7): Established because they were specified as contraindications or administrations requiring 
precautions on the thalidomide package insert.  
 
4.3 Obtaining informed consent  
Prior to the start of the RCT or long-term open trial, the principal investigator(s) or sub-investigator(s) at 
each center will ensure that the subject is given full and adequate oral and written information, which has 
been approved by an IRB, about the nature, purpose, possible risk, and benefit of the study. The subject’s 
signed and dated informed consent must be obtained before conducting any study procedures. The subject 
should be given the opportunity to ask questions and allowed time to consider the information provided.  
The principal investigator(s) / sub-investigator(s) as well as the subject who has received full and adequate 
written and oral information should sign/seal and date the informed consent document. 
However, if it is difficult for the subject to sign/seal due to the progression of the primary disease, 
signed/sealed written consent can be obtained from a legal representative based on confirmation of the 
subject’s intent to participate in the trial.  
If a study coordinator gives supplementary explanations to the subject, the study coordinator should also 
sign/seal and date the consent document together with the investigator or sub-investigator. A copy of the 
consent document and explanation document will be given to the subject and the original copy of the 
consent document is to be retained at the clinical trial site.  
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The principal investigator, sub-investigator, or study coordinator will confirm whether a subject who has 
given consent is also consulting with other clinics or hospitals. If the subject is indeed consulting with other 
clinics or hospitals, his/her primary physician there must be notified about the subject’s study participation.  
  
4.4 Obtaining consent for FPF300 safety management  
Prior to the start of the RCT period, the principal investigator or a sub-investigator must obtain informed 
consent regarding FPF300 Safety Management from the subject and the drug management assistant based 
on the subject’s comprehensive understanding of drug management.  
 
4.5 Pre-trial examination 
After obtaining the written informed consent from a patient, the pre-study (screening) examination of that 
subject is to be performed.  
 
4.6 Provision of new information to subjects 
When the principal investigator or a sub-investigator obtains important information that could affect the 
intention of a subject to consent to the study, the details of the information are to be explained immediately 
to the subject in question, and confirmation will be obtained of the subject’s intent to continue with the 
study. The principal investigator or a sub-investigator should record the date of explanation, the name of the 
person who provided the explanation, the details of the explanation, and the subject's intent to continue to 
participate in the study as well as the date such confirmation is made on any relevant documents, such as 
the subject’s patient chart, etc. 
Furthermore, if necessary, the principal investigator will revise the Informed Consent Form and the 
Explanation Document for approval by the IRB. If one or more subjects have already participated in the 
study, then the principal investigator or sub-investigator must explain the new revisions to the consent form 
and re-obtain the subject’s signature. 
 
4.7 Registration and allocation 
After screening is conducted, the patient will be registered for enrollment in the trial. Registration will, in 
principle, be done via facsimile to the Patient Registration Center.  
4.7.1 Registration 
Facsimile registration is possible only during the working hours of the Patient Registration Center, and 
should be conducted according to the following procedures.  
(1) The principal investigator or a sub-investigator will fill in a "Patient Registration Form" and send the 
30/92
 - 31 - 
 
document to the Patient Registration Center. In principle, the original copy of the "Patient Registration 
Form" should be stored in the subject’s medical records.  
(2) If the Patient Registration Center has found queries or deficits in the contents of the "Patient 
Registration Form," the Center will immediately contact the investigator and confirm the relevant 
contents. The Patient Registration Center will inform the investigator about the subject’s participation 
eligibility based on the information in the "Patient Registration Form." 
(3) The Patient Registration Center will send a message of either "Confirmation of Eligibility" or "Notice 
of Ineligibility" to the principal investigator, the sub-investigator, or the coordinating investigator by 
facsimile (fax). The “Confirmation of Eligibility” document will contain the subject’s identification 
code number and the allocated drug number. 
(4) The principal investigator or the sub-investigator will start the trial treatment after he/she has received 
the notice of eligibility and has confirmed that the patient has been enrolled in the study as an eligible 
subject. The "Confirmation of Eligibility" or " Notice of Ineligibility" will be stored in the subject’s 
medical records. 
The principal investigator and sub-investigator may not administer the study drug until the enrollment and 
randomization of the subject is complete.  
 
4.8 Handling of unregistered subjects 
If a patient is not randomized due to ineligibility or other reasons, that patient will not be registered and 
will not be included as an enrolled subject in the study. The principal investigator or a sub-investigator 
should explain to the patient that his/her enrollment in the trial is not possible.  
 
4.9 Allocation/Randomization 
Based on a Study Drug Allocation Table created using a reproducible method, the allocation coordinator 
will randomly allocate study drugs, and submit the Study Drug Allocation Table to the Patient Registration 
Center. The allocated drugs will be supplied to the institutional study sites by the coordinating investigator 
promptly after the study starts.  
 Allocation to the active product (thalidomide) or comparator (placebo) group will be performed by the 
registration center, and by a dynamic allocation method based on the allocation adjustment factors of serum 
VEGF values (≥ 3000 and < 3000) and the existence or non-existence of pleural effusion at the time of 
screening. The patients will be randomized at a 1:1 ratio of the active product (thalidomide) or comparator 
(placebo) group based according to a computer program based on appropriate computer algorithms created 
by the registration center. 
 The principal investigator or a sub-investigator will administer the study drug(s) with the code number 
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notified by the Patient Registration Center.  
 
Rationale 
The VEGF values and pleural effusion amounts are vital prognostic factors for patients with Crow-Fukase 
syndrome, and are primary and secondary evaluation parameters in this study. Therefore, the use of these 
parameters as allocation adjustment factors is considered to be critical to reducing bias between the two 
groups.  
 
4.10 Blinding of study drug  
4.10.1 Blinding method  
The measures to be taken by the allocation coordinator to maintain the blinding of the drug until the 
unblinding period are described as follows.  
 
The study drug is to be blinded according to the following procedures.  
(1) After the allocation coordinator has ensured that the external appearance and packaging of 
thalidomide and placebo to be used are indistinguishable from each other, he/she will perform random 
allocation of the study drug using a reproducible method.  
(2) The principal investigator must not change the evaluation for any subject who experiences a serious 
adverse event (SAE) in the event that an emergency key is unsealed. In addition, a record should be 
made of the unscheduled early unsealing of an emergency key that has been unblinded, and the 
specific key and record are to be presented to the allocation coordinator. 
(3) At the time of unbinding, the allocation coordinator must ensure that the Study Drug Allocation Table, 
storage envelope, and other relevant documents have remained in a sealed state.  
(4) At the time of unbinding, the allocation coordinator must ensure that the blinding of all study drugs 
has been maintained (all un-administered and unused study drugs are to be collected and checked to 
determine that they have remained sealed, and that all emergency keys have not been broken or 
unsealed). 
 
4.10.2 Method of maintaining blinding of study drug 
In this study, the maintenance of blinding might be obstructed due to serum VEGF examination results. 
Therefore, serum VEGF examination are to all be centrally measured at a central laboratory, and the 
examination results should not be disclosed to any external entity (such as study subjects, principal 
investigators, and sub-investigators) from the time study drug administration starts for each subject until the 
unblinding (temporary data fixation after the conclusion of randomized controlled testing of all subject 
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cases). In addition, the results will be stored at the central laboratory, and after announcement of the 
temporary data fixation, they will be reported to the data managers and statisticians. Prior to the 
announcement of the unbinding by the allocation coordinator, no measurement for the serum VEGF will be 
made other than the centralized measurements. 
Furthermore, following the screening of serum VEGF, the results are to be promptly transmitted from the 
central laboratory to each study site and used as an allocation adjustment factor..  
 
4.11 Pregnancy 
 To ensure patient safety in accordance with Thalidomide Education and Risk Management System 
(TERMS ®) (FPF300 Investigator initiated clinical trial version), the principal investigator must notify the 
coordinating investigator and study drug provider of any pregnancies of patients being administered the 
study drug as well as of partners of male subjects to whom the study drug is being administered (including 
positive pregnancy test results). Follow-up monitoring of the pregnancy must include confirmation of 
occurrences such as spontaneous abortion, artificial abortion, delivery details, presence or absence of any 
congenital defects or abnormalities, and the outcome of complications for the mother or the newborn. 
 
5. Study drug 
For details and handling specifications of the study drug, refer to the separate attached Investigator's 
Brochure. The details of the study drug used in this study are as follows.  
 
5.1 Active product (FPF300） 
Generic name Thalidomide 
Code number FPF300 
Structural formula (and 
mirror-image isomer)  
 
Dosage forms No. 2 hard capsule formulation containing 100 mg thalidomide  
Storage conditions Stored at room temperature 
 
5.2 Comparator (FPF300 placebo) 
The placebo capsules do not contain thalidomide and their outer appearance is indistinguishable from the 
active products.  
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5.3 Packaging and labeling of study drug 
Study drug external packaging (FPF300 and FPF300 placebo) 
Identical packaging and labeling are used for the randomized-controlled and the long-term open study 
drugs. 
However, the drug code number will be attached to the label only for the randomized control study, but not 
for the long-term open trial.  
 
 
 
 
 
 
 
 
 
 
 
 
5.4 Management of study drug 
(1) After the start of the trial, the coordinating investigator should promptly distribute the study drug to 
the principal investigator of each study site. 
(2) In accordance with the Standard Operating Procedure (SOP) submitted by the principal investigator 
through the head of each study site, the study drug administrator of the study site must appropriately 
store and maintain the study drug at room temperature. In addition, the drug must be handled and 
dispensed in accordance with the TERMS® (FPF300 Investigator initiated clinical trial vesion).  
(3) The principal investigator will create a document explaining the storage conditions of the supplied 
study drug and its handling conditions, including expiration date (the SOP described above is 
applicable to the document, since the information is recorded in the SOP ). In addition, the principal 
investigator should distribute this document to relevant personnel including the head of the study site, 
sub-investigators, study collaborators, and the study drug administrator. 
  
 
Manufacturing No./Expiration date:                /                
Storage method: Store in a locked container with limited access  
Coordinating investigator (representative) name, title, and address: 
Chiba University Hospital, Neurology Dept.,  
Satoshi Kuwabara 
1-81-1 Inohana, Chuo-ku, Chiba City, Chiba Prefecture  
Subject ID code： 
Study use FPF300 （100mg) 
 
7 capsules × 52 PTP sheets  
= 364 capsules 
 
Drug Code No. 
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6. Study method 
Randomized controlled trial: FPF300 or FPF300 placebo 
6.1 Randomized controlled trial  
In this study period, either FPF300 or FPF300 placebo will be used as the study drugs. After the screening 
examination is conducted, the patient will be registered and randomized. Administration dosage and 
method are described below. Each time the study drugs are prescribed, FPF 300 safety management 
compliance should be confirmed. (25.4) 
  
6.1.1 Administration dosage, methods, and schedule 
(1) Administration schedule 
① The first day of study drug administration is defined as day 1, and the first day of each subsequent 
cycle is also defined as day 1. 
② The length of a cycle is set at 28 days (4 weeks), and a total of 6 cycles (24 weeks) will be conducted; 
however, at the conclusion of study drug administration (after 24 weeks), administration will be 
permitted until the day before testing and observation. 
③ Dexamethasone (Decadron tablets, 0.5 mg) will be administered concomitantly with the study drug a 
total of 4 times from day 2 to day 5; however, if dexamethasone cannot be administered on day 2 for 
unavoidable reasons, its administration should be started by Day 4 at the latest. 
④ Patients will be hospitalized at the beginning of study drug administration and will remain in the 
hospital, in principle, for ≥3 weeks. 
 
(2) Dosage and administration method 
① One capsule of the study drug will be administered once per day before bedtime every other day. 
② Starting on Day 8, the dose will be increased in accordance with the dose escalation criteria. 
③ Dexamethasone (Decadron tablets, 0.5 mg) will be administered at a dose of 12 mg/m2 once per day 
(maximum dose 20 mg/day, decimals to be rounded off) after breakfast for 4 days during each cycle  
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28 Day  1 2 3 4 
One cycle 
Study drug（FPF300 or FPF300 placebo) 
Dexamethasone 
5 
Administered for a 4-day period at 12 mg/m2/day
（maximum dosage 20 mg/day) after breakfast 
Increase of study drug 
1 capsule every other day 
1 capsule 
daily 
2 capsules 
daily 
Day   1 7 
8 
14 
15 28 
3 5 
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Rationale for Dosage and Schedule Settings 
Multiple myeloma, a disease closely related to Crow-Fukase syndrome, has had numerous studies 
reporting the usage methods and dose of thalidomide for the treatment of multiple myeloma in Japanese 
patients. The proper use20 and clinical guidelines21 for thalidomide for the treatment of multiple myeloma 
state that the maximum tolerated dose (MTD) for Japanese patients is approximately 300 mg/daily, and 
increasing the dosage to 400 mg/daily and above is problematic due to the occurrence of adverse events. In 
addition, Murakami et al. 22 reported that in a survey of thalidomide dosage at 15 institutions by the Japan 
Myeloma Study Group, the initial, maximum, and maintenance doses were, 111.0 ± 31.5, 204.8 ± 86.8, and 
163.0 ± 95.2 mg/day, respectively. In numerous cases, thalidomide is maintained at a dose range of 
100-200 mg/day, which has been reported to show sufficient efficacy. The aforementioned guidelines20 
specify that, "Dosing should start with 100 mg/day oral administration of thalidomide, and, if there are no 
side effects, this can be increased to 200 mg/day after one (1) week. If there are no serious side effects, 
further increase is also possible." 
Moreover, the Assessment Report29 for THALED Capsule 100 determined that, despite there not being 
any clear details in any published papers or reports relating to the safety and efficacy of thalidomide and no 
determination of the safety of high doses that exceed those used in dose increment plans for domestic 
clinical trials (maximum 400 mg/day), 100-400 mg once per day is an appropriate dosing method and dose 
amount for domestic clinical trials. Furthermore, there have been reports regarding the administration 
amounts of thalidomide for Crow-Fukase syndrome of doses ranging from 100 mg every other day to 200 
mg/day17-19, and therefore the efficacy of each dose level has been recognized. 
Based on the above information, it is thought that the optimal dose level for the efficacious and safe 
treatment of Japanese patients with Crow-Fukase syndrome is within the range of 100-400 mg/day. 
Therefore, to ensure safety in this study, the initial dose level was set to 100 mg every other day and taking 
into account the 48 week study period, the maintenance level dose was set to 200 mg/day.  
 
6.1.2 Dose escalation criteria 
After day 7, if the absence of skin abnormalities and hematological toxicity (reduced neutrophil count 
and/or reduced platelet count) of Grade 3 or higher has been confirmed, the study drug dosage will be 
increased from one capsule every other day to one capsule every day. 
After day 14, if the absence of skin abnormalities and hematological toxicity (reduced neutrophil count 
and/or reduced platelet count) of Grade 3 or higher has been confirmed, the study drug dosage will be 
increased from one capsule every day to two capsules every day. The administration period for each dose is 
set at ≥7 days and the final dose escalation should be completed within 28 days. 
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Study drug (FPF300 or FPF300 placebo) dosage increase levels 
 
6.1.3 Dose maintenance criteria 
Following the completion of dose escalation, if the absence of skin abnormalities and hematological 
toxicity (reduced neutrophil count and/or reduced platelet count) of Grade 3 or higher has been confirmed, 
the study drug dosing regimen of two capsules every day will be maintained. 
 
6.1.4 Dose reduction criteria 
If skin abnormalities or hematological toxicity (reduced neutrophil count and/or reduced platelet count) of 
Grade 3 or higher occur, the dose must be reduced by one dose level. Dose reductions due to other adverse 
events will be determined based on the assessment of the principal investigator or sub-investigator. 
 
Study drug（FPF300 or FPF300 placebo) dosage level decrease (in the case of dosage reduction from two 
capsules daily) 
 
6.1.5 Re-administration/Reincrease criteria  
Reincrease, following suspension or dose reduction due to adverse events, should follow the 
administration method, dose escalation criteria, and maintenance criteria described above. In the event of a 
reincrease following a reduction due to adverse events, the dose reincrease should be to the dose being 
administered before the reduction. The administration period for each dose is ≥7 days; no period is set for 
the completion of a dose increase. Re-administration of the drug following a suspension should begin with 
the same dose as from before the suspension.  
 
Study drug (FPF300 or FPF300 placebo) dosage increase method 
Starting dosage Dosage level increment 
One capsule every other day 
＋1 +2 
One capsule daily Two capsules daily 
Study drug (FPF300 or FPF300 placebo) dosage decrease method  
Administered 
dosage 
Decreased dosage level 
Two capsules daily 
－1 －2 －3 
One capsule daily 
One capsule every other 
day 
Termination 
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6.1.6 Termination criteria for randomized controlled trial 
The principal investigator or sub-investigator will terminate the trial when one of the following criteria is 
met. 
(1) When adverse events occur even when the dose level has been reduced to the minimum level in 
accordance with the dose reduction criteria and when termination is deemed necessary by the principal 
investigator or sub-investigator. 
(2) When adverse events occur making the continuation of study drug administration difficult and 
termination is deemed necessary by the principal investigator or sub-investigator. In the event of 
subacute exacerbation during the randomized comparative study period, administration should not be 
terminated and the patient should be transitioned into the long-term, open trial period. 
(3) When a patient requests his/her withdrawal from the study. 
(4) When study drug administration is deemed unsuitable by the principal investigator or sub-investigator. 
(5) When termination of the study drug is deemed necessary by the principal investigator or 
sub-investigator. 
(6) When a patient is found to be pregnant. 
(7) When continued enrollment in the study is deemed impossible for any other reason by the principal 
investigator or sub-investigator. 
Other than in case (3), the day of termination is not the day the adverse event resulting in termination 
occurred, but the day that the principal investigator or sub-investigator decided that termination was 
necessary. 
 
6.2 ECG monitoring (during hospital admission)  
(1) Prior to study drug administration 
Prior to study drug administration, ECG monitoring is performed for at least 24 hours to confirm the 
absence of clinically relevant or serious findings. 
(2) After study drug administration 
During study drug administration, ECG monitoring is performed for 3 weeks, in principle, to confirm the 
absence of clinically relevant or serious findings. 
 
6.3 Concomitant drugs and therapies from the start of the RCT period to the end of the long-term 
open trial period 
6.3.1 Dexamethasone 
In accordance with the dosage administration and method (6.1.1), dexamethasone should be administered 
and used concomitantly with the study drug; however, if dexamethasone cannot be administered on day 2 
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for unavoidable reasons, its administration should be started by Day 4 at the latest. Dexamethasone will be 
administered using commercially available 0.5mg Decadron tablets and  its information will be obtained 
from the most recent package insert. However,  during the long-term open trial period the dosage forms of 
dexamethasone are not specified. 
 
6.3.2 Prohibited drugs and therapies  
(1) Antitumor therapy: 
Chemotherapy, hormone therapy, immunotherapy, antibody therapy, and radiotherapy. 
(2) Other study drugs used for an antitumor effect 
(3) Steroid therapy (oral, injection), except for dexamethasone in the long-term open trial period 
(4) Thalidomide, melphalan, bortezomib, and lenalidomide 
(5) β-blockers  
Rationale 
Established in consideration of possible influence on efficacy and safety evaluations.  
 
6.4 Criteria for early transition from the randomized controlled trial to the long-term open trial 
period  
In the event of subacute exacerbation of the primary disease during the random comparative study period, 
the patient should be transitioned early to the long-term open trial period. Determination of subacute 
exacerbation of the primary disease is conducted by the principal investigator or sub-investigator. 
The principal investigator(s) or sub-investigator(s) at each center will ensure that the subject is given full 
and adequate oral and written information, which has been approved by IRB, about the nature, purpose, 
possible risk, and benefit of the study. The subject’s signed and dated informed consent must be obtained 
before conducting any study procedures. The subject should be given the opportunity to ask questions and 
allowed time to consider the information provided.  
The principal investigator(s) / sub-investigator(s) or subjects who received full and adequate written and 
oral information should sign/seal and date the consent document. 
However, if it is difficult for the subject to sign/seal due to progression of the primary disease, 
signed/sealed written consent can be obtained from a legal representative.  
If a study coordinator gives supplementary explanations to the subject, the study coordinator should also 
sign/seal and date the consent document together with the investigator or sub-investigator. A copy of the 
consent document and explanation document is given to the subject and the original copy of the consent 
document is retained at the clinical trial site.  
After the transition to the long-term open trial, the primary investigator or sub-investigator will fax the 
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Transition Notification Form to the Patient Registration Center in a timely manner. 
 In principle, the dosage, administration method, and administration schedule of the study drug in the 
long-term open trial should be followed as described in 6.6.1 and 6.6.2. However, when patients meet the 
early transition criteria(a sudden increase in disease activity and the exacerbation of symptoms), the 
principal investigator or sub-investigator can, with due consideration of the patient’s safety, decide to 
shorten the administration period of each dosing level as well as complete dose escalation early in order to 
reach the maintenance level.  
 
6.4.1 Definition of subacute exacerbation of primary disease 
When clinical symptoms are exacerbated, a chest X-ray and other tests are performed as deemed 
necessary. Subacute exacerbation is determined to have occurred if either of the following is observed and 
if subacute exacerbation is deemed present by the principal investigator or sub-investigator. 
(1) Increase of ONLS total score of ≥2 compared to the beginning of the RCT period, or ≥1 level 
exacerbation of pleural effusion size. 
*Pleural effusion size: Assessed with a chest X-ray in a sitting or standing position. Computed tomography 
is also used as deemed necessary. 
Small……..Accumulation of up to 1/4 of the pulmonary field 
Moderate…Accumulation of up to 1/3 of the pulmonary field 
Large……..Accumulation of up to 1/2 of the pulmonary field 
(2) Body weight increase of 5 kg/month 
Increase in body weight of ≥5 kg in less than 1 month. Measured at any visit at the discretion of the 
principal investigator or sub-investigator. 
 
6.5 Criteria for transitioning from the RCT to the long-term open trial 
Patients who have completed the RCT period or who have met the criteria for early transition from RCT 
will move on to the long-term open trial period. Transition to the long-term open trial period should be 
conducted within 6 weeks after the completion of the RCT period. 
 Prior to the start of the long-term open trial, the principal investigator(s) or sub-investigator(s) at each 
center will ensure that the subject is given full and adequate oral and written information, which has been 
approved by IRB, about the nature, purpose, possible risk, and benefit of the study. The subject’s signed 
and dated informed consent must be obtained before conducting any study procedures. The subject should 
be given the opportunity to ask questions and allowed time to consider the information provided.  
The principal investigator(s) / sub-investigator(s) or subjects who received full and adequate written and 
oral information should sign/seal and date the consent document. 
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However, if it is difficult for the subject to sign/seal due to progression of the primary disease, 
signed/sealed written consent can be obtained from a legal representative. 
If a study coordinator gives supplementary explanations to the subject, the study coordinator should also 
sign/seal and date the consent document together with the investigator or sub-investigator. A copy of the 
consent document and explanation document is given to the subject and the original copy of the consent 
document is retained at the clinical trial site.  
 At the completion of the randomized controlled trial period, the principal investigator will submit a 
Patient (Case) Report document to the data management division in a timely manner and maintain copies.  
 
Long-term open study period: FPF300 
6.6 Long-term open trial period 
In this period, FPF300 will be used as the study drug. Patients who have moved on to the long-term open 
trial period will be administered FPF300. Upon transition, the primary investigator or a sub-investigator 
will immediately fax the Transition Notification Form to the Patient Registration Center. Each time the 
study drug is prescribed, the investigator or sub-investigator should confirm FPF300 safety management 
compliance (25.4). 
 
6.6.1 Administration dosages, methods, and schedule 
(1) Administration schedule 
① The first day of study drug administration is defined as day 1, and the first day of each subsequent 
cycle is also defined as day 1. 
② The length of a cycle is set at 28 days (4 weeks), and a total of 12 cycles (48 weeks) will be 
conducted; however, at the conclusion of study drug administration (after 48weeks), administration 
will be permitted until the day before testing and observation. 
③ Patients will be hospitalized at the start of study drug administration and will generally remain 
hospitalized for more than 3 weeks. 
 
(2) Dosage and administration method 
① One capsule (100 mg) of the study drug will be administered once per day before bedtime every other 
day. 
② Starting on Day 8, the dose will be increased in accordance with the dose escalation criteria. (section 
6.5.2) 
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Rationale for Dosage and Schedule Settings 
Multiple myeloma, a disease closely related to Crow-Fukase syndrome, has had numerous studies 
reporting the usage methods and dose of thalidomide for the treatment of multiple myeloma in Japanese 
patients. The proper use20 and clinical guidelines21 for thalidomide for the treatment of multiple myeloma 
state that the maximum tolerated dose (MTD) for Japanese patients is approximately 300 mg/daily, and 
increasing the dosage to 400 mg/daily and above is problematic due to the occurrence of adverse events. In 
addition, Murakami et al. 22 reported that in a survey of thalidomide dosage at 15 institutions by the Japan 
Myeloma Study Group, the initial, maximum, and maintenance doses were, 111.0 ± 31.5, 204.8 ± 86.8, and 
163.0 ± 95.2 mg/day, respectively. In numerous cases, thalidomide is maintained at a dose range of 
100-200 mg/day, which has been reported to show sufficient efficacy. The aforementioned guidelines20 
specify that, "Dosing should start with 100 mg/day oral administration of thalidomide, and, if there are no 
side effects, this can be increased to 200 mg/day after one (1) week. If there are no serious side effects, 
further increase is also possible." 
Moreover, the Assessment Report29 for THALED Capsule 100 determined that, despite there not being 
any clear details in any published papers or reports relating to the safety and efficacy of thalidomide and no 
determination of the safety of high doses that exceed those used in dose increment plans for domestic 
clinical trials (maximum 400 mg/day), 100-400 mg once per day is an appropriate dosing method and dose 
amount for domestic clinical trials. Furthermore, there have been reports regarding the administration 
amounts of thalidomide for Crow-Fukase syndrome of doses ranging from 100 mg every other day to 200 
mg/day17-19, and therefore the efficacy of each dose level has been recognized. 
Based on the above information, it is thought that the optimal dose level for the efficacious and safe 
treatment of Japanese patients with Crow-Fukase syndrome is within the range of 100-400 mg/day. 
Therefore, to ensure safety in this study, the initial dose level was set to 100 mg every other day and taking 
into account the 48 week study period, the maintenance level dose was set to 200 mg/day, which can be 
increased up to 300 mg/day in case of subacute exacerbation. 
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6.6.2 Dose escalation criteria 
After day 7, if the absence of skin abnormalities and hematological toxicity (reduced neutrophil count 
and/or reduced platelet count) of Grade 3 or higher has been confirmed, the study drug dosage will be 
increased from one capsule every other day to one capsule every day. 
After day 14, if the absence of skin abnormalities and hematological toxicity (reduced neutrophil count 
and/or reduced platelet count) of Grade 3 or higher has been confirmed, the study drug dosage will be 
increased from one capsule every day to two capsules every day. The administration period for each dose is 
set at ≥7 days and the final dose escalation should be completed within 28 days. 
 
Study drug (FPF300) dose level escalation   
 
6.6.3 Dosage maintenance criteria 
Following the completion of dose escalation, if the absence of skin abnormalities and hematological 
toxicity (reduced neutrophil count and/or reduced platelet count) of Grade 3 or higher has been confirmed, 
the study drug dosing regimen of two capsules every day will be maintained. 
 
Study drug (FPF300) dose escalation method 
Starting dose  Dose level 
100 mg（one capsule）every 
other day 
＋1 +2 
100 mg（one capsule）daily 200 mg（two capsules）daily 
28 day  
One cycle 
Study drug（FPF300） 
1 
Increase of Study drug increase dosage 
100mg every other day 
100mg daily
200mg daily 
day1 7 
8 
14 
15 28 
3 5 
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6.6.4 Thalidomide dose escalation criteria and dexamethasone concomitant usage criteria after early 
transition from RCT to long-term open trial 
 In the event of subacute exacerbation of the primary disease;  
The study drug dosage will be increased to three capsules every day. If subacute exacerbation still 
persists, in spite of this dose escalation, dexamethasone can also be administered concomitantly. 
 Definition of subacute exacerbation of the primary disease  
When clinical symptoms are exacerbated, a chest X-ray and other tests are performed as deemed 
necessary. Subacute exacerbation is determined to have occurred if either of the following is observed 
and if subacute exacerbation is deemed present by the principal investigator or sub-investigator. 
(1) Increase of ONLS total score of ≥2 compared to the beginning of the RCT period, or ≥1 level 
exacerbation of pleural effusion size. 
*Pleural effusion size: Assessed with a chest X-ray in a sitting or standing position. Computed tomography 
is also used as deemed necessary. 
Small……..Accumulation of up to 1/4 of the pulmonary field 
Moderate…Accumulation of up to 1/3 of the pulmonary field 
Large……..Accumulation of up to 1/2 of the pulmonary field 
 
(2) Body weight increase of 5 kg/month 
Increase in body weight of ≥5 kg in less than 1 month. Measured at any visit at the discretion of the 
principal investigator or sub-investigator. 
 
6.6.4.1 Dexamethasone administration dosage and method  
Dexamethasone should be administered at a dose of 12 mg/m2 once per day either orally or intravenously 
after breakfast for 4 days (maximum dose 20 mg/day; calculated based on the patient’s body weight at the 
initial dexamethasone administration for the long-term open trial period , decimals to be rounded off). The 
timing of the initial dosing of dexamethasone is not specified. In principle, following the initial dose,  
dexamethasone should be administered  from day 2 to day 5 of the specified 28-day (4-week) study drug 
administration cycle; however, as long as safety can be confirmed via the assessment of the principal 
investigator or sub-investigator, it is possible for the administration timing to be changed. 
 
6.6.5 Thalidomide dose escalation criteria and dexamethasone concomitant usage criteria after early 
transition from RCT to long-term open trial 
 In principle, the dosage, administration method, and administration schedule of the study drug in the 
long-term open trial should be followed as described in 6.6.1 and 6.6.2. However, when patients meet the 
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early transition criteria(a sudden increase in disease activity and the exacerbation of symptoms), the 
principal investigator or sub-investigator can, with due consideration of the patient’s safety, decide to 
shorten the administration period of each dosing level as well as complete dose escalation early in order to 
reach the maintenance level.  Furthermore, on the determination of the principal investigator or 
sub-investigator upon  due consideration of the patient’s safety, the study drug dose can be increased to 
the maximum of three capsules (300 mg) and dexamethasone can be concomitantly administered as 
necessary. 
 
  
Dexamethasone concomitant usage 
 
 
 
 
 
 
 
 
 
 
 
6.6.6 Dose reduction criteria  
If skin abnormalities or hematological toxicity (reduced neutrophil count and/or reduced platelet count) of 
Grade 3 or higher occur, the dose must be reduced by one dose level. Dose reductions due to other adverse 
events will be determined based on the assessment of the principal investigator or sub-investigator. 
 
 
 
 
 
 
 
 
 
11 12 13 14 
Study drug short-term increased dosage 
schedule (example) 
100㎎ every 
  
100㎎ daily 
200㎎ daily 
300㎎ daily 
Day  1 3 4 10 
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Study drug（FPF300）dose level reduction 
 
6.6.7 Re-administration/Reincrease criteria  
Reincrease, following suspension or dose reduction due to adverse events, should follow the 
administration method, dose escalation criteria, and maintenance criteria described above. In the event of a 
reincrease following a reduction due to adverse events, the dose reincrease should be to the dose being 
administered before the reduction. The administration period for each dose is ≥7 days; no period is set for 
the completion of a dose increase. Re-administration of the drug following a suspension should begin with 
the same dose as from before the suspension. 
 
6.6.8 ECG monitoring (during hospital admission)  
(1) Prior to study drug administration 
Prior to study drug administration, ECG monitoring is performed for at least 24 hours to confirm the 
absence of clinically relevant or serious findings. 
(2) After study drug administration 
During study drug administration, ECG monitoring is performed for 3 weeks, in principle, to confirm the 
absence of clinically relevant or serious findings. 
 
6.6.9 Termination criteria 
The principal investigator or sub-investigator should terminate the trial when one of the following criteria is 
met. 
(1) When adverse events occur even when the dose level has been reduced to the minimum level in 
accordance with the dose reduction criteria and when termination is deemed necessary by the principal 
investigator or sub-investigator. 
(2) When adverse events occur making the continuation of study drug administration difficult and 
Study drug (FPF300) dose reduction method  
Dose  Dose reduction level 
200 mg 
（two capsules）
daily 
－1 －2 －3 －4 
100 mg 
（one capsule）  
daily 
100 mg 
（one capsule） 
every other day 
Termination － 
300 mg 
（three capsules） 
daily 
200 mg 
（two capsules） 
daily 
100 mg 
（one capsule)  
daily   
100 mg 
（one capsule）
every other day 
Termination 
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termination is deemed necessary by the principal investigator or sub-investigator. In the event of 
subacute exacerbation during the randomized comparative study period, administration should not be 
terminated and the patient should be transitioned into the long-term open trial period. 
(3) When a patient requests his/her withdrawal from the study. 
(4) When study drug administration is deemed unsuitable by the principal investigator or sub-investigator. 
(5) When termination of the study drug is deemed necessary by the principal investigator or 
sub-investigator. 
(6) When a patient is found to be pregnant. 
(7) When continued enrollment in the study is deemed impossible for any other reason by the principal 
investigator or sub-investigator. 
Aside from (3), the day of termination is not the day the adverse event resulting in termination occurred, 
but the day that the principal investigator or sub-investigator decided that termination was necessary. 
 
7. Examination and observation criteria and times  
7.1 Screening examination and observation criteria  
After obtaining the written consent of the patient, the following parameters will be examined and observed.  
・Patient background: sex, date of birth, height, body weight1), PS2), complications, medical history, 
pre-treatment history, time of occurrence of Crow-Fukase syndrome, history of allergy, and history of 
adverse reactions. 
・Motor function test (manual muscle testing, MMT3), grip strength4), and ONLS5)） 
・Confirmation of subjective and objective symptoms: edema and skin abnormalities (pigmentation)  
・Observation of adverse events 
・Blood pressure and pulse count6)  
・Blood tests: 
Blood counts: red blood cells (RBCs), hemoglobin, platelet, white blood cells (WBCs, WBC differential 
count)  
Biochemical tests: total protein, albumin, electrolytes (Na, K, and Cl), BUN, serum creatinine value, 
CPK, Ch-E, total bilirubin value, AST, ALT, ALP, LDH, γ-GTP, CRP, Ig-G, Ig-A, Ig-M, protein fraction, 
and blood sugar 
Coagulation function tests: fibrinogen, FDP, APTT, PT, INR 
・Serum VEGF7) 
・Urinalysis: urinary sugar (qualitative) and protein (qualitative)  
・Chest X-ray8) 
・ECG9) 
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・Chest, abdominal, and bone CT inspection10)  
・Pregnancy test11) 
 
To reduce the burden of the examinations performed to confirm a patient’s eligibility for the study, the CT 
examinations and general test results obtained 4 weeks before administration of the study drug can be used.  
 
1）During the study period, a uniform body weight measurement should be used to the extent possible.  
2）To be determined based on the PS (refer to section 25.1). 
3）For the MMT the same individual is to perform the measurements throughout the study period, to the 
extent that is possible. The determination of MMTs is to be based on the following.   
5 (normal): with maximum resistance and G-force, can be moved over the entire movement range. 
4 (good): with a specific degree of resistance and G-force, can be moved over the entire movement 
range.  
3 (fair): in the absence of resistance, can be moved over the entire movement range in resistance to 
G-force.  
2 (poor): can be moved over the entire movement range when no G-force is applied.  
1 (trace): only a small amount of muscle contraction can be confirmed but joint movement does not 
occur.  
0 (zero): even muscle contraction cannot be confirmed.  
4）For grip strength, the same dynamometer should be used throughout the study period. Grip width should 
be the width where the second joint of the index finger is nearly at a right angle, and the width at the first 
test should be uniform throughout the study period. A Smedley-type hand dynamometer should be used and 
grip measurements should be performed following the procedures below. 
①When a stable standing position is possible: spread legs a bit apart with arms hanging down naturally, 
and grip to the fullest extent possible.  
When a stable standing position is not possible: while sitting upright with arms hanging down naturally, 
grip to the fullest extent possible.  
*Care should be taken that the dynamometer does not come in contact with the body or clothing as 
much as possible. 
②Measurements of both sides should be taken one time each, first with the right hand and then with the 
left hand.  
5）The ONLS (25.2) will be evaluated. 
6）Blood pressure and pulse count should be measured while in a stable sitting position.  
7）Serum VEGF will be centrally measured. Venous blood will be collected when the other blood test 
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parameters are analyzed, and the specimens should be centrifuged after setting them aside for 1 hour. The 
samples will be maintained at -20°C until measurements are performed. These will be collected with the 
specimens for serum VEGF measurements by the individuals responsible at the clinical testing and 
measuring institution and will be subsequently analyzed there. 
8）For the chest X-ray, a frontal view will be examined. From the first examination and throughout the 
study period, the position (standing or sitting) and the imaging direction (AP or PA) should be consistent to 
the extent that is possible. The standards used should be PA and AP for the standing and sitting positions, 
respectively.  
9）The ECG should be recorded when the patient is in a relaxed state, as a 12-lead ECG in a recumbent 
position.  
10）Chest, abdominal, and bone CT inspection should be routine inspections. The slice width should be 10 
mm or less and uniform throughout the study period. The determinations will be made by an Efficacy and 
Safety Evaluation Committee. Images that will serve as original reference materials should be stored in a 
digital DICOM format or as film and will be submitted to the Efficacy and Safety Evaluation Committee.  
11）A urine test (at sensitivity of HCG 25 IU/L and above) should be used for the pregnancy test. Details 
are as stipulated in the TERMS® (FPF300 Investigator initiated clinical trial version). 
 
7.2 Examination and observation parameters during randomized controlled trial and long-term open 
study  
During the study, the following standard examination and observations will be performed.  
 
・Confirmation of drug-taking compliance status and concomitant medications  
・Motor function test（MMT, grip strength, and ONLS） 
・Confirmation of subjective and objective symptoms: edema and skin disorder (pigmentation)  
・Observation of adverse events 
・Body weight, blood pressure, and pulse count  
・Blood tests: 
Blood counts: RBC, hemoglobin, platelet, WBC, and WBC differential  
Biochemical tests: total protein, albumin, electrolytes (Na, K, and Cl), BUN, serum creatinine value, 
CPK、Ch-E, total bilirubin value, AST, ALT, ALP, LDH, γ-GTP, CRP, Ig-G, Ig-A, Ig-M, and urinary M 
protein qualitative test（immunofixation)12), protein fraction, blood sugar, and serum free light chain13) 
Coagulation function tests: fibrinogen, FDP, APTT, PT, and INR 
Endocrine (in the morning following fasting and at rest): ACTH, cortisol, HGH, somatomedin C, LH, 
FSH, E2 (estradiol), testosterone, prolactin, TSH, FT3, FT4, and insulin 
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・Serum VEGF 
・Urinalysis: urinary sugar (qualitative) and protein (qualitative)  
・Chest X-ray 
・ECG 
・Chest, abdominal, and bone CT inspection  
・Nerve conduction study14) 
・Respiratory function test15) 
・Pregnancy test 
・Confirmation of FPF300 safety management conformance 
・QOL survey (SF-36)16) 
 
12）The M protein qualitative test is to be determined by the performance of immunofixation at the Clinical 
Laboratory of Chiba University Hospital.  
13）Serum free light chains will be centrally measured at the Clinical Laboratory of Chiba University 
Hospital. Venous blood will be collected when other blood test parameters are analyzed, and specimens will 
be immediately centrifuged. The samples will be maintained at -20°C until serum measurements are 
performed. These samples will be collected with the specimens for serum VEGF measurements to be 
performed by the responsible individuals at the clinical testing and measuring institution and measured at 
the Clinical Laboratory of Chiba University Hospital. 
14）The nerve conduction study will be conducted on both sides according to the following procedure. The 
determinations will be made by the Efficacy and Safety Evaluation Committee and the documents reporting 
the findings (including the original waveforms) will be submitted to the Efficacy and Safety Evaluation 
Committee. 
①Different electrodes should be connected to the venter (median nerve at abductor pollicis brevis and 
ulnar nerve at abductor digiti minimi muscle) and indifferent electrode set on the tendon. The skin 
temperature should be maintained, in principle, at 33°C and above.  
②Negative electrodes will stimulate the wrist (within a 3-cm vicinity of the palmar carpal joint line) 
and elbow (in the case of the median nerve, the cubital fossa and in the case of ulnar nerve, cubital 
tunnel, with the positive electrode in close vicinity to the negative electrode), and compound muscle 
action potential will be recorded. To examine the ulnar nerve, the elbow should be placed at a 90° bent 
angle. The latency will be measured from the baseline of the negative component of the CMAP to the 
point of start-up.   
③Measurement should be taken of the latency differences between the time of stimulation of the hand, 
wrist, and elbow to the CMAP derivation, and the motor nerve conduction speed will be measured for 
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the distance between the wrist and elbow. Similarly, for the ulnar nerve, the elbow should be maintained 
at a 90° bent angle during distance measurement times. 
④For the F-wave tests, the stimulation should be performed with the negative electrode at the wrist 
(within a 3-cm vicinity of the palmar carpal joint line) and 16 wave departures will be recorded. The 
F-wave sensitivity should be raised up to 200 µV, and the F-wave minimal latency times will be 
measured. 
15）For the respiratory function test, measurements will be taken of the lung VC using a spirometer. 
16) At each survey point, the primary investigator, a sub-investigator, or a study collaborator will provide 
the patient with a Questionnaire Form to complete. However, when writing is difficult due to conditions 
such as the progress of the primary disease, a legal representative or a person who is  appointed a drug 
management assistant can fill out the form on the patient’s behalf. After collection, the forms will be 
submitted to the data management division and copies will be maintained. In cases where survey 
performance is difficult due to a worsening of the disease conditions of the patient, this information will be 
recorded in that patient's case report form(CRF).. 
 
7.3 Examination and observation parameters at completion of randomized controlled trial, early 
transition, long-term open study, or termination 
At the completion or termination of the study, the following standard examination is to be performed at 
that time.  
・Confirmation of drug-taking compliance status and concomitant medications  
・Motor function test (MMT), grip strength, and ONLS） 
・Confirmation of subjective and objective symptoms: edema and skin disorder (pigmentation)  
・Observation of adverse events17) 
・Body weight, blood pressure, pulse count  
・Blood tests: 
Blood counts: RBC, hemoglobin, platelet, WBC, and WBC differential  
Biochemical tests: total protein, albumin, electrolytes (Na, K, and Cl), BUN, serum creatinine value, 
CPK, Ch-E, total bilirubin value, AST, ALT, ALP, LDH, γ-GTP, CRP, Ig-G, Ig-A, Ig-M, urinary M 
protein qualitative test (immunofixation), protein fraction, blood sugar, and serum free light chain 
Coagulation function tests: fibrinogen, FDP, APTT, PT, and INR 
・Serum VEGF 
・Urinalysis: urinary sugar (qualitative) and protein (qualitative) 
・Chest X-ray 
・ECG 
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・Chest, abdominal, and bone CT inspection  
・Nerve conduction study 
・Respiratory function test 
・Pregnancy test 
・Confirmation of FPF300 safety management conformance 
・QOL survey (SF-36)  
 
17）Observation will be conducted for the 4-week period after the completion of drug administration, to 
determine adverse events occurring up to the examination day at the termination of study drug 
administration, regardless of any or no causal relationship with the study drug. For cases involving the 
occurrence of continuous adverse events, follow-up observation is to be performed even after the 4-week 
period until, to the extent that it is possible, a recovery is observed. The occurrence of side effects (where 
a causal relationship with the study drug is undeniable) should be monitored even if they occur after the 
examination day at the termination of study drug administration. However, this does not extend to cases of 
chronic symptoms due to conditions such as the worsening of the primary disease or complications, in 
hospital transfers, or the commencement of post-treatment therapies. 
 
7.4 Pregnancy test (only for female subjects of reproductive potential) 
For female patients who may possibly become pregnant, pregnancy tests (urine test: 25 IU/L sensitivity 
and above) are to be performed at the periods stated below, and the study drug will be prescribed upon 
confirmation of negative pregnancy test results by the principal investigator or sub-investigator. 
In the case of a false positive or positive test result, in accordance with the package insert of the in vitro 
diagnostic product, reexamination should be performed and an obstetrician-gynecologist should be notified.  
In addition, after termination of the study drug administration, the principal investigator or a 
sub-investigator will confirm that the pregnancy test result was negative. 
Pregnancy tests will be performed at intervals of no longer than 4 weeks.  
 
(1) 4 weeks before start of study drug administration  
(2) 2 weeks before start of study drug administration  
(3) Within 24 hours before prescription of study drug (every prescription time)  
(4) After study drug administration or during termination 
(5) 4 weeks after termination or discontinuation of study drug administration 
 
Follow-up observation will be performed according to the "25.3 Appendix: Examination and Observation 
Not necessary if confirmation is made of no 
sexual activity during the 4-week period 
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Schedule." 
 
7.4.1 Definition of female subjects of reproductive potential 
Female subjects who do not fall under any of the following categories: 
(1) Female subjects who have reached natural menopause (45-year-old or older and have not had a 
menstrual period for 1 year or longer),  
(2) Female subjects whose uteri were removed 
(3) Female subjects whose ovaries were removed. 
 
7.5 Validity observation parameters 
7.5.1 Reduction rate of serum VEGF after 24 weeks 
The primary endpoint is the Serum VEGF reduction rate and its equation is as follows:  
 
 
 
The serum VEGF value measured at Day 1 of Cycle 1 prior to the study drug administration is set as the 
baseline value, and the reduction of VEGF value after 24 weeks will be divided by the baseline value for 
the serum VEGF reduction rate. However, for subjects who transitioned early to the long-term open trial 
period, or withdrew/discontinued during the RCT period, the serum VEGF value at 24 weeks will be 
replaced with the final serum VEGF value measured in the RCT period as a substitute value. 
 
7.5.2 Evaluation of motor function index 
Evaluations are performed using the MMT, grip strength, and ONLS. 
 
7.5.3 Evaluation of median-ulnar nerve motor conduction velocity, compound muscle action potential 
(CMAP) amplitude, and F-wave latency 
Evaluations are performed using a nerve conduction study. 
 
7.5.4 Evaluation of M protein 
M protein quality evaluations are performed using immunofixation in blood samples. 
 
7.5.5 Evaluation of pleural effusion 
The quantity of the pleural effusion is evaluated using a computed tomography (CT) scan (the level of 
maximum left ventricular diameter). 
Serum VEGF reduction rate = 
Serum VEGF level at the baseline – serum VEGF level at 24 weeks 
Serum VEGF level at the baseline at 24 weeks 
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7.5.6 Evaluation of vital capacity (VC)  
Vital capacity (VC) is evaluated using a spirometer. 
 
7.5.7 Evaluation of body weight 
Body weight is evaluated. 
 
7.5.8 Evaluation of QOL 
A Japanese version of the comprehensive health-related QOL scale SF-36v2™, which is an evaluation 
method is used to evaluate the QOL. 
 
7.5.9 Central review of nerve conduction velocity and pleural effusion 
These effects are evaluated according to the standards independently determined by the Data and Safety 
Monitoring Committee. 
 
7.6 Examination of safety and observation parameters 
7.6.1 Determination of adverse events 
Adverse events refer to undesirable effects (including abnormal changes in laboratory test values), 
symptoms, and diseases experienced by patients who have been administered the study drug. A causal 
relationship with the study is not evaluated. 
In principle, adverse events are evaluated using the Common Terminology Criteria for Adverse Events 
(CTCAE version 4.0) by listing incidences of the adverse events and assigning grades. In this trial, events 
that occurred between obtaining consent from the patients and starting administration of the study drug are 
defined as adverse events of this trial. 
 
7.6.2 Serious adverse events (SAEs) 
SAEs refer to those that fall under the following categories: 
(1) Death 
(2) Is life threatening 
(3) Disability 
(4) May lead to disability 
(5) Hospitalization or prolongation of existing hospitalization 
(6) Serious medical events according to the above (1) ~ (5)  
(7) Congenital diseases or abnormalities that occur in future generations 
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7.6.3 Non-serious adverse events  
Non-SAEs refer to all adverse events other than those determined to be “serious,” and are determined by a 
principal investigator or a sub-investigator. 
 
7.6.4 Recovery from adverse events and causal relationship with the study drug 
The disappearance of adverse events is considered to be the absence of adverse events or the recovery of 
the subject’s condition to the grade prior to the administration of the study drug. To determine the causal 
relationship between adverse events and the study drug, the general condition of subjects, complications, 
concomitant medications, combination therapy, and temporal relationship are taken into consideration. For 
the determination of a causal relationship, two classifications are used: “Not related” and “Cannot be ruled 
out” 
 
7.7 Blood sampling for pharmacokinetic studies (only for specific medical institutions that implement 
the test)  
For the pharmacokinetic study, blood is sampled according to the following points at the specific medical 
institutions that implement the test. The amount of blood sampled is 5 mL at a time, and the total should not 
exceed 15 mL. 
 
(1) Single 100-mg dose: a long-term open trial period – cycle 1, day 2; 24 ± 1 hours after and immediately 
before administration 
(2) Repeated 100-mg doses: a long-term open trial period – cycle 1, day 15; 24 ± 1 hours after and 
immediately before administration 
However, if the long-term open trial period – cycle 1 day 15 is not the final 100-mg dose, the 
measurement is taken on the final day of the 100-mg dose. 
(3) Repeated 200- or 300-mg doses: a long-term open trial period – 48 weeks after (the final day) or at the 
time of termination. 
24 ± 1 hours after administration. 
The time of blood sampling must be recorded accurately. 
 
8. Responding and reporting at the time of adverse events  
8.1 Responding at the time of adverse events 
A principal investigator or a sub-investigator who confirms the occurrence of an adverse event is to 
provide appropriate treatment for the patient and include accurate notes on the incidence in the medical 
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record and case report. 
Regardless of the existence of a causal relationship with the study, adverse events that occur up to the 
final day of the study drug administration are to be observed for 4 weeks after the final dose. In cases where 
the adverse events persist, the observation should continue beyond 4 weeks and last until the events are 
resolved as possible. Side effects, which causal relationship with the study drug cannot be ruled out, should 
be monitored as much as possible even if they appear after the final examination day of the study drug 
administration. However, if symptoms have become chronic due to worsening of the underlying diseases 
and complications, and observation becomes difficult due to hospital transfer and the beginning of the 
post-treatment period, the observation will not be limited to those discussed above.  
If the administration of the study drug is discontinued or treatment is required for adverse events, 
subjects are to be informed of these developments. 
If adverse events occur and a principal investigator determines it necessary for the subject to be made 
aware of the allocated treatment, the principal investigator can open the emergency key. In such a case, the 
principal investigator must promptly report the incidence to the allocation coordinator. The emergency key 
is then opened according to the “8.3 Procedure for opening the emergency key.” 
 
8.2 Responding to SAEs 
(1) In case of occurrence of a Serious Adverse Event (SAE), the principal investigator or sub-investigator 
must provide appropriate treatment regardless of causal relations between the SAE and study drug. 
(2) The principal investigator will immediately report the SAE to the head of the trial site as well as the 
coordinating-investigator and study drug provider, regardless of causal relations between the SAE and 
study drug.  
(3) The coordinating-investigator will verify the content of the SAE report obtained from the principal 
investigator, and report the information of the SAE to the principal investigators of the other trial 
sites.  
(4) The principal investigator of each trial site will verify the content of the SAE report obtained by the 
coordinating-investigator, discuss the content with the coordinating-investigator as necessary, and 
report his/her opinion as the principal investigator to the coordinating-investigator (including the 
necessity of reporting the SAE to MHLW). 
(5) When the principal investigators determine that there is a need to report the SAE to the Minister of 
MHLW, the coordinating-investigator will report the SAE.  
(6) In cases where SAEs that have occurred in other trial sites are reported to the Minister of MHLW, the 
principal investigator will submit the AE report obtained by the coordinating -investigator and submit 
it to the head of the trial site as soon as possible. 
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(7) When additional information related to the SAE is obtained, the principal investigator of the trial site 
where the SAE has occurred will additionally report it to the head of the trial site immediately as well 
as to the coordinating-investigator and study drug provider. Additional information will be treated 
according to 4–6. 
 
8.3 Procedure for opening the emergency key 
When there are SAEs which causal relationship with the study drug cannot be ruled out and a principal 
investigator determines that the opening of the emergency key is necessary to ensure the safety of the 
patient, the principal investigator or a sub-investigator will open the emergency key of the affected subject. 
When the emergency key is opened, the principal investigator should promptly report to the director of the 
study site and prepare a report on the reason and process of the opening, which will then be submitted to 
the director of the study site and the allocation coordinator. If blinding is released, the principal investigator 
should immediately discontinue administration of the study drug and terminate the subject’s participation in 
the trial. 
 
8.4 Expected side effects  
Adverse events that occurred in the domestic phase II trial investigating the use of thalidomide for 
multiple myeloma are noted below. For other possible side effects, please refer to the Investigator’s 
Brochure. 
<The domestic phase II trial of thalidomide administration had a total of 37 multiple myeloma cases > 
 
 
 
 
 
 
 
 
 
 
 
 
 
Side effects  Frequency (Grade 3 or higher)  
Ischemic heart disease  1/37 cases (2.7%)  
Reduction in hemoglobin  3/37 cases (8.1%)  
Lymphopenia  3/37 cases (8.1%)  
Neutropenia  9/37 cases (24.3%)  
Leukopenia  5/37 cases (13.5%)  
Perforation of the digestive tract  1/37 cases (2.7%)  
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A total of 25 Crow-Fukase syndrome cases were administered thalidomide at our institution (for 6 months or 
less from the first dose)> 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. Endpoints 
9.1 Randomized controlled trial period  
9.1.1 Primary endpoints 
The primary endpoint is the Serum VEGF reduction rate and its equation is as follows:  
 
 
 
 
The serum VEGF value measured at Day 1 of Cycle 1 prior to the study drug administration is the 
baseline value, and the reduction of VEGF value after 24 weeks will be divided by the baseline value for 
the serum VEGF reduction rate. However, for subjects who transitioned early to the long-term open trial 
period, or withdrew/discontinued during the RCT period, the serum VEGF value at 24 weeks will be 
replaced with the final serum VEGF value measured in the RCT period as a substitute value. 
  
Adverse events  Frequency 
Grade 2  
 Rashes  5/25 cases (20%)  
 Hyperkalemia  1/25 cases (4%)  
Deep vein thrombosis  1/25 cases (4%)  
 Serum Cr increase 1/25 cases (4%)  
Grade 3  
 Rashes  1/25 cases (4%)  
 Leukopenia  1/25 cases (4%)  
Gastrointestinal ileus  1/25 cases (4%)  
PT extension 1/25 cases (4%)  
Enteritis  1/25 cases (4%)  
Grade 4  
 Bradycardia  1/25 cases (4%)  
 Carinii pneumonia  1/25 cases (4%)  
Serum VEGF reduction rate = 
Serum VEGF level at the baseline – serum VEGF level at 24 weeks 
Serum VEGF level at the baseline at 24 weeks 
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Rationale for setting the Primary Endpoint 
This syndrome has a diverse set of clinical symptoms, making it is difficult to evaluate improvement of 
clinical symptoms in a direct and objective manner. Furthermore, if the focus is on the improvement of 
clinical symptoms, it is difficult to limit the main evaluation items to one or even two. According to recent 
research results, the proliferation of plasma cells and associated excess secretion of VEGF are fundamental 
factors involved in the diverse clinical picture of this syndrome and these factors have been verified to 
cause a myriad of clinical symptoms1-4. Therefore, the association of serum VEGF values and motor 
function improvement (grip strength, median nerve conduction velocity, and median nerve amplitude) was 
examined at Chiba University Hospital Department of Neurology in 21 patients for whom transplant 
treatments or thalidomide + dexamethasone treatments were instituted for Crow-Fukase syndrome. 
Temporal changes in the serum VEGF before and after the treatment were confirmed, and the VEGF 
value stabilized at 12 and 24 weeks after the treatment began in the transplant and thalidomide groups 
(Figures 1 and 2), respectively. Therefore, if the serum VEGF value is used as the main evaluation criteria, 
thalidomide should be administered for at least 24 weeks or longer. Furthermore, this trial is a 
placebo-controlled, double-blind study and while dexamethasone is introduced as the base treatment for the 
placebo group, its effects are not expected to be relevant. Therefore, if the base treatment is continued for 
24 weeks or longer for the placebo group, subacute exacerbation, and life prognosis may be affected. For 
that reason, the randomized, double-blind comparative study period was set at 24 weeks. Furthermore, 
examination of the relationship between 24-week serum VEGF reduction rate and motor function 
improvement (grip strength, median nerve conduction velocity, and median nerve amplitude) indicated that 
when VEGF was reduced, motor function improved (Figure 3 and Table 1). 
The serum VEGF shows quantitative and measurement errors between institutions, which can be 
prevented by using central measurements, and since the treatment period can be objectively evaluated by 
blinding the VEGF values, it was set as the Primary Endpoint. 
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Figure 1. Temporal changes in vascular endothelial growth factor (VEGF) value of transplant group 
 
Figure 2. Temporal changes in vascular endothelial growth factor (VEGF) value of thalidomide group 
 
 
Figure 3. The relationship between 24-week vascular endothelial growth factor (VEGF) reduction rate and 
motor function using grip strength as well as median nerve conduction velocity and amplitude 
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Table 1. Relationship between 24-week vascular endothelial growth factor (VEGF) reduction and motor 
function 
Motor 
function  
VEGF reduction rate after 
24 weeks 
Number of 
subjects 
Median 
value 
Mean 
value 
Standard 
deviation 
*P-value 
Grip 
strength  
<0.6 8 -5.5 1.4 24.4 0.17 
≥0.6 11 11.5 12.6 7.6 
Median 
nerve 
conduction 
velocity 
<0.6 6 2.0 3.2 6.3 0.0012 
≥0.6 
9 12.0 12.3 4.9 
Median 
nerve 
amplitude 
<0.6 8 -0.2 -0.2 1.6 0.001 
≥0.6 
10 3.7 3.5 1.3 
*P value: permutation test 
  
9.1.2 Secondary endpoints  
9.1.2.1 Secondary efficacy endpoints 
(1) Serum VEGF value 
(2) Achievement of serum VEGF target value (1000 pg/mL) 
(3) Motor function (MMT, grip strength, and ONLS)  
(4) Median and ulnar nerve motor conduction velocity, CMAP amplitude, F-wave latency 
(5) M protein quality (blood and immunofixation)  
(6) Amount of pleural effusion 
(7) VC  
(8) Body weight  
(9) QOL (SF-36)  
 
Rationale for setting secondary efficacy endpoints 
(1) Adopted to evaluate temporal changes in serum VEGF value. 
(2) Adopted to evaluate the relationship between the clinical effect and changes in serum VEGF by 
determining the serum VEGF target value at which the clinical effect is confirmed and comparing the 
achievement rate. 
(3) (4) Crow-Fukase syndrome is always accompanied by peripheral neuropathy and motor impairment due 
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to a high degree of muscle weakness, which significantly interferes with the patient’s daily activities and 
QOL. For the 21 patients with Crow-Fukase syndrome who were treated with thalidomide-dexamethasone 
or transplantation therapy at our hospital, when serum VEGF was decreased, motor function (grip strength, 
median nerve conduction velocity, and median nerve amplitude) improved. Therefore, the MMT (a motor 
function index), grip strength, ONLS (motor function evaluation scale for chronic peripheral nerve disease), 
and median-ulnar nerve conduction study parameters were adopted as secondary efficacy endpoints. 
(5) Crow-Fukase syndrome is a multiple myeloma-related disease associated with plasma cell tumor and, 
therefore, M protein quality was adopted because it reflects the disease. 
(6) Accumulation of pleural effusion in Crow-Fukase syndrome is a direct cause of respiratory and heart 
failure, which is directly linked to the life expectancy and prognosis. Therefore, it was adopted because it 
could be an index that reflects the disease and the life expectancy prognosis. 
(7) Phrenic nerve paralysis, which is a feature of peripheral neuropathy in Crow-Fukase  
syndrome, causes respiratory failure and, therefore, was adopted because it could be considered an index 
that reflects the disease. 
(8) In Crow-Fukase syndrome, the accumulation of pleural and pericardial effusion is a direct cause of 
respiratory and heart failure, which is directly linked to the life expectancy and prognosis. It was adopted 
because it could be an index for quantitatively evaluating the water retention trend of the whole body and 
reflects the disease prognosis and life expectancy. 
(9) Crow-Fukase syndrome is a refractory systemic disease accompanied by muscle weakness in all four 
limbs; therefore, the evaluation of QOL becomes important. The Japanese edition of the SF-36 is 
internationally used to evaluate the QOL of other peripheral nerve diseases, and because it is consistent in 
evaluating QOL for this syndrome, it was adopted as a secondary efficacy endpoint. 
 
9.1.2.2 Secondary safety endpoint 
Adverse events  
 
Rationale for setting secondary safety endpoint 
These were selected to evaluate the safety of thalidomide administration for Crow-Fukase syndrome. 
 
9.2 Long-term open trial period  
9.2.1 Primary endpoint 
Adverse events  
 
Rationale for setting the primary endpoint 
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They were selected to evaluate the safety of thalidomide administration for Crow-Fukase syndrome. 
 
9.2.2 Secondary endpoints  
(1) Serum VEGF value 
(2) Achievement of serum VEGF target value (1000 pg/mL) 
(3) Motor function (MMT, grip strength, and ONLS)  
(4) Median-ulnar nerve motor conduction velocity, CMAP amplitude, and F-wave latency  
(5) M protein quality (blood and immunofixation)  
(6) Amount of pleural effusion 
(7) VC  
(8) Body weight  
(9) QOL (SF-36)  
 
Rationale for setting secondary efficacy endpoints 
(1) Adopted to evaluate temporal changes in serum VEGF value. 
(2) Adopted to evaluate the relationship between the clinical effect and changes in serum VEGF by 
determining the serum VEGF target value at which the clinical effect is confirmed and comparing the 
achievement rate. 
(3) (4) Crow-Fukase syndrome is always accompanied by peripheral neuropathy and motor impairment due 
to a high degree of muscle weakness, which significantly interferes with the patient’s daily activities and 
QOL. For the 21 patients with Crow-Fukase syndrome who were treated with thalidomide-dexamethasone 
or transplantation therapy at our hospital, when serum VEGF was decreased, motor function (grip strength, 
median nerve conduction velocity, and median nerve amplitude) improved. Therefore, the MMT (a motor 
function index), grip strength, ONLS (motor function evaluation scale for chronic peripheral nerve disease), 
and median-ulnar nerve conduction study parameters were adopted as secondary efficacy endpoints. 
(5) Crow-Fukase syndrome is a multiple myeloma-related disease associated with plasma cell tumor and, 
therefore, M protein quality was adopted because it reflects the disease. 
(6) Accumulation of pleural effusion in Crow-Fukase syndrome is a direct cause of respiratory and heart 
failure, which is directly linked to the life expectancy and prognosis. Therefore, it was adopted because it 
could be an index that reflects the disease and the life expectancy prognosis. 
(7) Phrenic nerve paralysis, which is a feature of peripheral neuropathy in Crow-Fukase syndrome, causes 
respiratory failure and, therefore, was adopted because it could be considered an index that reflects the 
disease. 
(8) In Crow-Fukase syndrome, the accumulation of pleural and pericardial effusion is a direct cause of 
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respiratory and heart failure, which is directly linked to the life expectancy and prognosis. It was 
adopted because it could be an index for quantitatively evaluating the water retention trend of the whole 
body and reflects the disease prognosis and life expectancy. 
(9) Crow-Fukase syndrome is a refractory systemic disease accompanied by muscle weakness in all four 
limbs; therefore, the evaluation of QOL becomes important. The Japanese edition of the SF-36 is 
internationally used to evaluate the QOL of other peripheral nerve diseases, and because it is consistent in 
evaluating QOL for this syndrome, it was adopted as a secondary efficacy endpoint. 
 
10. Statistical analysis  
The details are separately provided in the statistical analysis plan. 
10.1 Analysis set  
10.1.1 Maximum analysis set (full analysis set, FAS)  
Subjects, who are registered in this trial and have been administered at least one dose of the study drug 
will be included in the FAS. However, subjects whose cases contain major violations of the protocol (such 
as no consent obtaining or early registration before the trial) will be excluded. 
 
10.1.2 Population compliance with the protocol (per protocol set, PPS)  
The PPS population subjects will exclude all subjects in the FAS population who meet any of the 
following major violations of the protocol. 
 Inclusion criteria violation 
 Exclusion criteria violation 
 Prohibited concomitant drug use violation 
 Prohibited concomitant therapy violation  
 Adherence rate less than 75% during the randomized comparative study or the long-term safety 
periods  
 
10.1.3 Safety analysis set  
Safety analyses will be performed on the SAF population subjects who are registered in the trial and 
received the assigned study drug at least once for each treatment group. 
 
10.2 Reason for setting the number of target subjects 
To date, there are no established standard treatment methods for Crow-Fukase syndrome, and 
melphalan-prednisolone combination therapy is often selected. According to an epidemiological study by 
Chiba University Hospital, the 24-week VEGF reduction rate with melphalan-prednisolone combination 
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therapy was 0.35 ± 0.20. In contrast, the 24-week VEGF reduction rate for the thalidomide-dexamethasone 
treatment group was 0.55 ± 0.21. Although there is no treatment result for dexamethasone monotherapy, 
VEGF reduction rate is expected to be about 0.1–0.2. Assuming that the 24-week VEGF reduction rate 
following placebo administration with dexamethasone base treatment and thalidomide in Crow-Fukase 
syndrome is 0.2 and 0.55 ± 0.25, respectively, under the conditions of a significance level of ± 5% and 
power of 80%, the calculations were performed using t statistics. To achieve significance, the required 
number of cases in a group is 10 cases. Considering incidental occurrences such as dropouts, we set 12 
cases per group with a total of 24 cases. 
 
10.3 Handling of cases 
In principle, the coordinating investigator and principal investigator will decide how to handle registered 
patients. If unforeseen problems occur, handling of the cases will be decided based on discussions with 
statistical advisers or members of the Efficacy and Safety Assessment Committee, if necessary. 
 
10.4 Handing of data 
At the time of data collection/calculation and analysis, the method of handling the data will be determined 
by the principal investigator and the coordinating investigator. However, if any problems occur, 
determinations will be made based on discussions with statistical advisors and members of the Efficacy and 
Safety Assessment Committee. The handling of QOL data will be determined separately. 
Missing test values will be replaced with substituted values and the details will be described in the 
statistical analysis plan. 
 
10.5 Statistical analysis endpoints and plan 
 The primary analysis for all efficacy endpoints will be performed on the FAS while the analyses on the 
PPS will be treated as reference data. Safety analyses will be performed on the SAF. 
 
10.5.1 Subject background 
The distribution of subject background data and summary statistics in each analysis set will be presented 
for each treatment group. For the nominal and ordinal variables, the category frequencies and ratios will be 
shown according to each treatment group. For the continuous variables, the summary statistics will be 
calculated for each group. For the nominal, ordinal, and continuous variables, the Chi-square test (Fisher’s 
exact probability test, when necessary), Wilcoxon rank sum test, and the t-test (significance level ± 0.05), 
respectively, will be used. 
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10.5.2 Endpoints 
10.5.2.1 Randomized controlled trial period(RCT)  
10.5.2.1.1 Primary endpoints  
The main objective of this trial is to evaluate whether the active product (thalidomide) can lower the 
24-week VEGF reduction rate significantly in the active product group in comparison to the placebo group 
(this being the primary endpoint). The examination of the null hypothesis, which states that the VEGF 
reduction rates of both active and placebo groups will be the same in the primary analysis, will be 
conducted using an analysis of covariance (ANCOVA). Covariates at that time will be the value of the 
VEGF level prior to treatment and the presence or absence of pleural effusion. In addition, the temporal 
change in the VEGF of each group will be presented as a sensitivity analysis, and the time measurement 
data will be analyzed using a linear mixed-effects model to secondarily confirm that the results do not 
deviate greatly from the analysis of the covariance results. The significance level is ± 5%, and a ± 95% 
confidence interval (CI) is calculated. 
 
10.5.2.1.2 Secondary efficacy endpoints 
The analyses of the secondary efficacy endpoints will be performed to support the discussion on the 
results of the primary analysis in this trial. In analyzing the secondary efficacy endpoints, the multiplicity 
will not be adjusted. Comparison between the groups will be analyzed as needed while the significance and 
confidence levels are ± 10% and 90%, respectively. 
Among the secondary endpoints, efficacy evaluation will be made on temporal changes in serum VEGF 
value, achievement of serum VEGF target value (1000 pg/mL), motor function (MMT, grip strength, and 
ONLS), median-ulnar nerve motor conduction velocity, CMAP amplitude (F-wave latency), M protein 
quality (immunofixation), amount of pleural effusion, VC, body weight, and QOL (SF-36). These 
parameters will be analyzed in the final analysis. 
 
10.5.2.1.3 Secondary safety endpoints 
The safety endpoints include the occurrence rates of overall SAEs and SAEs that are associated with the 
treatment such as decreased leukocyte-platelet, deep vein thrombosis, bradycardia, and peripheral 
neuropathy. For each evaluation parameter, a spreadsheet will be prepared and for the interval estimation of 
proportion, the accurate ± 95% CI with binomial distribution is calculated. Fisher’s exact probability test 
will be used to make a comparison between groups if needed. 
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10.5.2.2 Long-term open trial period  
10.5.2.2.1 Primary endpoints 
Primary endpoints include occurrence rate of overall SAEs and SAEs that are associated with the 
treatment of decreased leukocyte-platelet, deep vein thrombosis, bradycardia, and peripheral neuropathy. 
For each evaluation parameter, a spreadsheet will be prepared and for interval estimation of proportion, the 
accurate ± 95% CI with a binomial distribution is calculated. The Fisher’s exact probability test will be 
used to compare differences between the groups if needed. 
 
10.5.2.2.2 Secondary endpoints  
The analyses of the secondary efficacy endpoints will be performed to support the discussion on the 
results of the primary analysis in this trial. In an analysis of secondary endpoints, multiplicity is not 
adjusted. Comparison between groups is made as needed. The significance level is ± 10% and ± 90% 
confidence level is calculated. 
Among the secondary endpoints, efficacy evaluation will be made on temporal changes in serum VEGF 
value, achievement of serum VEGF target value (1000 pg/mL), motor function (MMT, grip strength, and 
ONLS), median-ulnar nerve motor conduction velocity, CMAP amplitude (F-wave latency), M protein 
quality (immunofixation), amount of pleural effusion, VC, body weight, and QOL (SF-36). These 
parameters wil be analyzed in the final analysis. 
 
10.5.2.3 Laboratory test values  
Changes in laboratory test values and other analysis are summarized as descriptive statistics. 
 
10.6 Interim analysis and early discontinuation of trial 
An interim analysis will not be performed. 
Upon the receipt of any new information that makes it clear that there is any safety issue affecting the 
continuation of the trial or that the efficacy of the trial therapy cannot be expected, early termination of the 
trial should be considered. In addition, if the Efficacy and Safety Assessment Committee give reports that 
there is concern from the prospective of safety or efficacy regarding the continuation of the trial and the 
principal investigators decide to terminate the trial, the trial should be terminated early. The results should 
be disclosed via publication. However, even if registration is discontinued early, a follow-up study will be 
conducted. 
 
10.7 Final analysis 
In the randomized controlled trial period, after the cases are fixed following the acquisition of the data for 
68/92
 - 69 - 
 
the main evaluation parameters, analysis will be performed. After administration of the study drug is 
completed for all subjects during the long-term open trial period and the data are fixed, the final analysis 
will be performed. A statistical analysis officer will prepare the summary of the analysis in an “analytical 
report of a randomized controlled trial period” and a “final analytical report,” which are to be submitted to 
the coordinating investigator and the principal investigators. The coordinating investigator should then 
summarize the content of the statistics report, and prepare a “comprehensive report of randomized 
controlled trial period” and a “final comprehensive report” that summarizes the conclusion of the entire 
trial, issues, interpretation and discussion of the results, and future policies are summarized from a clinical 
point of view, and then obtain approval from the principal investigators. 
 
11. Adherence to trial protocol and deviation from and violation of Good Clinical Practices (GCP) 
(1) The principal investigator or sub-investigator should record actions that deviate from the trial protocol 
regardless of the reason. 
(2) If the deviation from the protocol cannot be prevented and is necessary to avoid emergencies 
involving the study subjects or due to other medical reasons, the principal investigator should 
promptly submit a document describing the details and reason for the deviation to the director of the 
study site. In addition, the principal investigator should promptly report the details of the submitted 
document to the IRB through the director of the study site. 
 
12. Changes to the trial protocol, case report form (CRF), or analysis plan 
12.1 Revision of the trial protocol and CRF  
The trial protocol or case report form must be revised according to the following procedure: 
(1) If the coordinating investigator considers it necessary to initiate a revision, they are to submit the 
proposed amendments to the trial protocol, CRF, and new Investigator’s Brochure along with any 
other necessary documents and information to a principal investigator. 
(2) The coordinating investigator must provide sufficient time for the principal investigator to fully 
examine the documents and information (such as the proposed amendment to the trial protocol) and 
discuss them with the coordinating investigator. 
(3) After conferring with the coordinating investigator, the principal investigator must promptly submit 
the revised trial protocol and revised CRF to the director of the study site and obtain the approval of 
the IRB through the director of the study site. 
(4) If the director of the study site’s instructions based on the opinion of the IRB are within a permissible 
range for coordinating investigator but require revisions to the to the trial protocol or CRF, the above 
procedure must be gone through again for those revisions. 
69/92
 - 70 - 
 
 
12.2 Changes to analysis plan 
When any content of the statistical analysis plan (SAP) is changed, the statistical analysis staff will 
describe all changes in the statistical analysis report and the clinical study report. The history of revisions to 
the SAP must be recorded as well. 
 
13. Termination, suspension, or completion of trial 
13.1 Standards for termination or suspension of entire trial 
If the following information is obtained and the continuation of the entire trial is proven to be difficult, the 
coordinating investigator will discuss the termination or suspension of the entire trial with the principal 
investigators and make the necessary decision. 
(1) Occurrence of serious side effects that “could not be predicted.” 
(2) Information that indicates that the trend of incidences such as the number, frequency, and occurrence 
condition of “predictable” serious side effects cannot be predicted from the investigator's .brochure. 
(3) Information that indicates that SAEs that were determined to have no causal relationship to the study 
drug but because of are observed occurrence trends such as the number, frequency, and occurrence 
conditions are later determined to indeed have a causal relationship with the study drug that cannot be 
ruled out. 
(4) Research reports that indicate that occurrence trends such as the number, frequency, and conditions of 
side effects have changed significantly. 
(5) Research reports that indicate that there is a risk of serious diseases such as cancer, disabilities, and 
death  
(6) Information that indicates that the efficacy of the study drug cannot be expected in this trial.  
(7) Information that indicates that the study drug has no efficacy on the target disease. 
(8) Information regarding any marketed drugs which have the same ingredients as the study drug 
indicating a termination of manufacturing, import, or retail, or that the drug is being recalled or 
disposed of in order to prevent the occurrence or expansion of health and hygiene-related risks. 
 
13.2 Procedure for discontinuation or suspension of entire clinical trial 
If it is decided that the entire clinical trial should be discontinued or suspended after discussing the matter 
with the other principal investigators, the coordinating investigator must promptly provide the details and 
reasons for discontinuation or suspension in writing to the directors of the trial sites and the 
pharmaceuticals and medical device agencies (PMDA). Furthermore, all subjects who are 
mid-administration must be informed of the discontinuation or suspension immediately, and appropriate 
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changes to their treatment and processes must be made. 
 
13.3 Procedure for discontinuation or suspension of the trial at respective trial site 
When the trial is discontinued or suspended, the principal investigator will promptly report the 
discontinuation or suspension to the director of the trial site in writing and explain the details in the 
document.  
When the principal investigator reports the discontinuation or suspension of the trial to the coordinating 
investigator, the coordinating investigator will notify in writing all other principal investigators involved in 
this clinical trial as well as the PMDA and provide adequate details. 
 
13.4 Completion of the trial 
After the completion of trial, the principal investigator will report the completion to the director of each 
clinical trial site and submit the summary of the trial results in a written form.  
  
14. Case report forms (CRFs) 
14.1 Confirmation of content of case reports by the principal investigator and notes on preparation 
(1) Following the completion of each trial period, the principal investigator or the sub-investigator 
prepares the CRFs, which are subsequently signed/sealed. The seal and signature on the CRFs must be 
identical to those in the “list of signatures and seals.” The principal investigator will submit the CRFs 
to the coordinating investigator and retain their copies at the trial sites. 
(2) When the sub-investigator has prepared the CRFs, or the study coordinator has transcribed 
information from the source documents into the CRFs, the principal investigator will check the 
contents for any issues before signing off on the CRFs. The CRFs will be submitted to the data 
management department. The CRFs should be prepared according to relevant, separately prepared 
SOPs created separately; for example, “SOP for changing and correcting CRFs” and “SOP for filling 
out CRFs”. 
 
 
14.2 Changes or corrections to contents of CRFs 
(1) Before submitting CRFs to the coordinating investigator, the following points should be noted. 
Upon changing, correcting, or making additions to CRFs, the principal investigator or the 
sub-investigator will follow the “SOP for changing and correcting CRFs” and “SOP for filling out 
CRFs,” which are to be prepared separately. 
(2) After submitting the CRFs to the coordinating investigator, the following points should be noted. 
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Upon changing, correcting, or making additions to the CRFs, the principal investigator or the 
sub-investigator will use a Data Clarification Form supplied by the data management department in 
order to make a record of the modifications. The principal investigator will submit the original record 
with his/her seal/signature to the coordinating investigator and retain a copy of the document. 
When the sub-investigator has prepared the document, or the study coordinator has transcribed 
information from the source documents into the document, the principal investigator will check the 
contents for any issues before signing off on the document. A copy of the document will be submitted 
to the data management department, as well.  
 
14.3 Specifying source documents (source data) 
In this trial, the following documents are considered source documents (source data). 
(1) Records related to the informed consent of subjects and information provided to subjects. 
(2) Medical records, nursing records, laboratory examination data, imaging films and other original data 
used to prepare the CRFs. Data stored in electronic charts are also considered source data.  
(3) Records associated with the administration of the study drug. 
(4) Documents or records associated with the clinical trial deemed necessary by the GCP . 
 
The items listed below are considered as source data when they are recorded in the CRF. However, if they 
are recorded in the medical records, the medical records in question will be considered as the source data. 
(1) Purpose of concomitant medication and concomitant therapy 
(2) Severity, Seriousness, and Outcome of adverse events/Determination and reasons for determination of 
causal relationships with the study drug  
(3) Comments by the principal investigator or the sub-investigator 
 
15. Storing and submitting source documents and other records 
15.1 Storing records by the clinical trial site 
Documents and records related to the trial are to be stored at the clinical trial sites as defined by the GCP, 
and are stored by the director of the clinical trial site until whichever of the following dates is the later 
among them. 
(1) The manufacturing and marketing approval date (if development is discontinued, 3 years after the 
discontinuation of development has been determined) of the study drug for its efficacy  
(2) Three years after discontinuation or completion of the trial. 
 
When records that should be stored by the clinical trial site or the IRB no longer need to be stored, the 
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principal investigator will notify the clinical trial site. 
 
15.2 Storage of records by the principal investigator 
Documents and records related to the trial to be stored by the principal investigator as defined by the GCP 
should be stored at a storage location deemed appropriate until whichever of the following dates is the later 
among them. 
(1) Five years from the manufacturing and marketing approval date of the study drug (if development is 
discontinued, 3 years after the discontinuation of development has been determined). However, for 
pharmaceutical products that require re-examination after the approval based on the provisions of the 
Pharmaceutical Affairs Law and when the completion of the re-examination is beyond 5 years, the 
completion date of re-examination is used. 
(2) Three years after the trial discontinuation or completion. 
 
16. Direct access to source documents/data 
The head of the clinical trial site and the principal investigator must assure access to all source documents 
during monitoring by a Contract Research Organization (CRO) designated by the principal investigator, 
audit, and inspections by the IRB or regulatory agencies. The CRO will confirm that the trial is 
appropriately conducted and the reliability of data is sufficiently ensured. The method for direct access and 
the monitoring period are separately defined in the monitoring procedures. 
 
17. Quality control and quality assurance of the trial  
17.1 Quality control (QC) 
A monitor will perform monitoring and confirm that the trial is being conducted in compliance with the 
trial protocol and GCP at the clinical trial sites. In addition, the monitor will directly view the records 
related to the trial such as source documents (source data) and confirm that the case reports and other 
reports are accurate. The monitor, a data manager, and a statistical staff will verify and confirm the data at 
each data handling stage. 
 
17.2 Quality assurance (QA)  
Quality assurance will be performed to ensure that the trial as well as collection, recording, and reporting 
of data are conducted appropriately and in compliance with the protocol and GCP. 
An auditor who is independent from all divisions conducting the trial (including but not limited to the 
Monitoring Division) will perform the audit of the clinical trial sites and other sites involved with the trial 
and verify whether quality assurance is being conducted appropriately.  
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18 Good Clinical Practice (GCP) 
18.1 Ethics and GCP 
The study will be conducted in adherence to ethical principles based on the Declaration of Helsinki, as 
well as Good Clinical Practice (GCP) and related regulatory requirements.  
 
18.2 Institutional review board（IRB） 
Prior to implementation of this trial, the institutional review board (IRB) will evaluate the ethical, 
scientific, and medical appropriateness of the trial. The trial will be performed after obtaining approval 
from the IRB. If the evaluation results of the IRB are “approved with modification,” the trial will be 
implemented after the protocol, case report forms, or informed consent forms are modified based on the 
review results. In addition, the IRB will continuously review whether the trial is being conducted 
appropriately at least once a year. 
 
19. Reparation of harm caused to a clinical trial subject and insurance matters 
If any harm is caused to a clinical trial subject as the result of the subject’s participation in the trial, the 
study site must take necessary and appropriate steps with respect to the harm, including steps towards the 
treatment of the harm. Notwithstanding the foregoing, there shall be no reparation to clinical trial subjects 
in this clinical trial, for the portion of medical costs that are to be borne by the clinical trial subjects as 
patients pursuant to the regulations, or for per diem, or for the compensatory payments comprising 
compensation to family members on bereavement, compensation of funeral expenses, compensation of 
disability, and compensation to disabled children. Additionally, if the harm is determined to have arisen out 
of the clinical trial subject’s intentional or gross negligence actions or inactions, it may not be eligible for 
the reparation hereunder.  
In order to discharge the liabilities under the law for damages inflicted by any harm that is attributable to 
this clinical trial, the Director of the Trial Promotion Center of Japan Medical Association will maintain 
liability insurance the covered persons under which shall be the principal investigators, the 
sub-investigators, the study sites, and the coordinating investigator, as and when a contract to that effect is 
entered into between the principal investigators or the study sites, on one hand, and the Trial Promotion 
Center of Japan Medical Association, on the other hand. Additionally, the principal investigators, and the 
sub-investigators shall maintain professional liability insurance. Furthermore, the study site shall maintain 
hospital liability insurance. 
 
20. Monetary compensation 
If subjects are financially compensated for their participation in the trial or are paid to alleviate an 
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associated burden, the payment is to be made from the grants of each study site according to the regulations 
of each medical institution. 
 
21. Agreement on publishing results 
The results of the clinical trial will be submitted as a report by the principal investigator to the head of the 
clinical trial site upon completion of this study. Results that do not meet expected outcomes despite the 
proper conduct of the clinical trial must also be disclosed via publication. If the Investigator is to present 
information obtained by this clinical trial at external professional academic meetings, the Investigator must 
obtain approval beforehand from other the other principal investigators and the study drug provider in 
writing. If the results are to be disclosed to the public, all subject’s personal information must be kept 
confidential and the principal investigators (including the coordinating investigator) as well as the study 
drug provider are to review the proposed manuscript. 
 
 This trial is being conducted as a supported research project (hereafter referred to as the “trial promoting 
research project”) by a Ministry of Health, Labour and Welfare Scientific Research Grant (Medical 
Technology Commercialization Research Project [Trial Promoting Research]). When the results of the trial 
promoting research project or a part or the whole progress report of such a project are published or 
presented at conferences, according to the implementation guideline of the trial promoting research project, 
a “research results publication notice” must be submitted to the Japan Medical Association trial promotion 
center. 
 
22. Attribution of intellectual property rights 
The copyright of documents prepared for the implementation of this trial, data obtained in this trial, 
findings, information, patent rights, and rights to apply for a patent (hereafter referred to as “intellectual 
property right”) are attributed to the Japan Medical Association as the implementing institution of the trial 
promotion research projects. However, based on contracts created between the Japan Medical Association 
and either the principal investigator (Chief investigator) the trial study site, the intellectual property rights 
may be attributed to the principal investigator, the trial study site, or all three entities for sharing of the 
property rights. 
The study drug provider can utilize the information obtained from the trial in order to apply for approval 
of manufacturing and selling pharmaceutical products related to the study drug (or import or part 
modification of the approval). In addition, the study drug provider can include the trial data in the product 
information summary. 
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23. Trial Implementation System (Attachment 1)  
23.1 Principal Investigators and Study Sites 
23.2 Trial Coordinating Investigator Committee  
23.3 Trial Coordinating Management Office 
23.4 Study Drug Provider 
23.5 Efficacy and Safety Assessment Committee 
23.6 Statistical Advisor  
23.7 Project Support Organizations 
23.7.1 Contract Research Organizations (CROs) 
23.7.2 Auditors 
23.7.3 Central Laboratory (serum VEGF)  
23.7.4 Central Laboratory (serum free light chain assay and M protein quality, immunofixation)  
23.7.5 Central Laboratory (blood concentration measurement)  
23.8 Other Related Organizations 
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25. Appendix 
25.1 ECOG Performance Status (PS) 
 
Performance Status Score 
 
Score 
 
 
Definition 
0 
Fully active, able to carry on all pre-disease activities without restriction. 
 
1 
 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light sedentary nature, e.g., light housework and office work. 
 
2 
 
Ambulatory and capable of all self-care but unable to carry out any work activities. Up 
and about more than 50% of waking hours. 
 
3 
 
Capable of only limited self-care, confined to a bed or chair more than 50% of waking 
hours. 
 
4 
 
Completely physically challenged and cannot carry out any self-care. Totally confined to 
a bed or chair. 
 
 
From Common Toxicity Criteria, Version 2.0 Publish Date April 30, 1999 
http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf 
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25.2 Overall neuropathy limitation scale (ONLS) 
 ① Arm Scale 
Does the patient have any symptoms in their hands or arms such as tingling, numbness or weakness? 
(Note: If “no”, please move on to the ② Leg Scale survey) 
Is the patient affected by their ability to: 
1. Wash and brush their hair 
□1. Not affected □ 2. Affected but not 
prevented □3. Prevented  
2. Turn a key in a lock 
□1. Not affected □2. Affected but not 
prevented □3. Prevented  
3. Use a knife and fork together (or a spoon, if a knife and 
fork are not used) 
  
□1. Not affected □2. Affected but not 
prevented □3. Prevented  
4. Can or cannot undo buttons or zips 
□1. Not affected □2. Affected but not 
prevented □3. Prevented  
5. Dress the upper part of their body excluding buttons or 
zips 
  
□1. Not affected □2. Affected but not 
prevented □3. Prevented  
6. Patient is unable to perform all the above (1 to 5)  
□1. Yes □2. Some of the movements are 
possible. 
＊If “yes”, check the applicable ones.  
Can the patient make a purposeful movement 
with their hands or arms? 
□1. Yes □2. No  
Arm Grade 
0 = Normal 
1 = Minor symptoms in one or both arms but not affecting any of the functions listed 
2 = Disability in one or both arms but not preventing any of the functions listed 
3 = Disability in one or both arms preventing, at least, one but not all functions listed 
4 = Disability in both arms preventing all functions listed, but purposeful movement still possible 
5 = Disability in both arms preventing all purposeful movements  
 
 Score (Arm Scale)  
□1. 0 □2. 1 □3 2 □4. 3  
□5. 4 □6. 5 
□1.No □2..Yes 
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② Leg Scale 
1. Does the patient have difficulty running or climbing stairs? □1. Yes □2. No 
2. Does the patient have difficulty walking? □1. Yes □2. No   
3. Does the patient’s gait appear abnormal? □1. Yes □2. No  
4. How do they move for about 10 meters (33 feet)? 
Without aid 
With one stick, crutch, or with someone’s assistance  
With two sticks, crutches, one stick, or with a crutch and 
assistance  
With a wheelchair 
 
□1. Yes □2. No  
□1. Yes □2. No  
□1. Yes □2. No  
 
□1. Yes □2. No  
5. If they use a wheelchair, can they stand and walk 1 m with 
the help of one person?  
□1. Yes □2. No  
6. All the above-described movements (1-5) are prevented 
□1. Yes □2. Some of the above movements 
are possible. 
＊If “yes”, check those movements that are 
possible. 
 Are they able to make some purposeful 
movements of their legs, e.g., reposition legs 
in bed? 
□1. Yes □2. No  
7. Does the patient use ankle foot orthoses or braces? 
□1. Yes □2. No  
If yes, please circle right/left.  
Leg Grade 
0 = Walking/climbing stairs/running not affected 
1 = Walking/climbing stairs/running is affected, but gait does not look abnormal 
2 = Walks independently but gait looks abnormal 
3 = Requires unilateral support to walk 10 meters (stick, single crutch, one arm) 
4 = Requires bilateral support to walk 10 meters (sticks, crutches, crutch and arm, frame) 
5 = Requires wheelchair to travel 10 meters, but able to stand and walk 1 m with the help of one person 
6 = Restricted to wheelchair, unable to stand and walk 1 m with the help of one person but able to make 
some purposeful leg movements 
7 = Restricted to wheelchair or bed most of the day, unable to make any purposeful movements of the legs 
 
Score (Leg Scale)  
□1. 0 □2. 1 □3. 2 □4. 3 □5. 4 □6. 5  
□5. 6 □6. 7 
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③ Total score (Arm Scale Score [0-5] + Leg Scale Score [0-7])  
Total Score (0-12)  
 
Is there any disorder other than peripheral neuropathy, 
which affects the above functions? 
 
□1. No □2. Yes 
(Please describe: )  
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Items Screening randomized controlled trial period long-term open trial period post-observation 
Period  4 weeks before 
Cycle 1 Cycle 2 Cycle 3 and later After completion of the trial  
drug administration (24 weeks 
later or early transition) or at 
discontinuation 
Cycle 1 Cycle 2 Cycle 3 and later After completion of the 
trial drug administration 
(48 weeks later) or at 
discontinuation 
after 4 
weeks 
Day１１） 
Standard 
Day81） 
Day15 
Day1 
（4 weeks）  
Day1 
（every 4 weeks ）  
Day1１） 
Standard 
Day81） 
Day15 
Day1 
（4 weeks） 
Day1 
（every 4 weeks ）  
Acceptable range for the test/observation -28～0 -10～0 +3 -3 -10 ±7 -7～0 +3 -3 -10 ±7  
Consent acquisition 12） ●      ●2）      
FAX to case registration center ●（Patient registration form ）     ●( Transition notification form )     
Confirm patient background ●            
Confirm drug administration condition   ● ● ● ●  ● ● ● ●  
Motor function test ● ●  ● ● ● ●9)  ● ● ●  
Confirm subjective/objective symptoms ● ● ● ● ● ● ● ● ● ● ●  
Observation of adverse events            ● 
Body weight ● ●  ● ● ● ●  ● ● ●  
Measurement of blood pressure and pulse ● ● ● ● ● ● ● ● ● ● ●  
Endocrine examination (with empty stomach)  ●     ●      
Blood and urine test ● ● ● ● ● ● ● ● ● ● ●  
Serum VEGF ● ●13）  ● ● ● ●  ● ● ●  
M protein quality  ●   ●8) ● ●   ●10) ●  
Serum free light chain  ●   ●8) ● ●   ●10) ●  
Chest X ray 3） ● ●  ● ● ● ●9)  ● ● ●  
Electro-cardiogram ● ● ●  ●8) ● ●9) ●  ●10) ●  
Chest and abdominal CT scan ●5） ●7）   ●8) ● ●9)   ●10) ●  
Nerve conduction test  ●   ●8) ● ●9)   ●11) ●  
Vital capacity (VC)  ●    ● ●9)   ●11) ●  
Pregnancy test4） ●6)           ● 
Confirmation of FPF300 safety management conformance            ● 
QOL survey (SF-36)  ●    ● ●9)   ●11） ●  
25.3 Test and observation schedule 
-83- 
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● The first day of drug administration in each period is defined as cycle 1 day 1 and each cycle is 
28 days long. After drug administration is completed in the randomized controlled trial period for the 
study drug (24 weeks) or in a long-term open trial period for the study drug (48 weeks), patients can 
continue with the drug until the day before the test/observation. 
 
1) To begin the administration of the study drug, patients are hospitalized for 3 weeks or longer. 
2) Consent must be obtained prior to beginning a long-term open trial period. 
3) In principle, chest X-rays are to be taken during the test period under the same conditions as the 
screening test. 
4) Pregnancy test should be performed at the study site on each drug administration date for female 
patients who could become pregnant. In addition, regardless of permission, a pregnancy test should 
be performed within 28 days from the previous test during the drug administration. Furthermore, 
when the transition period from the end of the study drug administration in a randomized controlled 
trial period to a long-term open trial period is 4 weeks or longer, a pregnancy test should be 
performed. 
5) Within 4 weeks prior to the beginning of the study drug administration in a randomized controlled 
trial period, and as part of the regular medical care, results obtained prior to the consent can be used. 
6) If it is confirmed that a patient had sexual intercourse within 4 weeks prior to the acquisition of 
consent, pregnancy tests are performed 4 and 2 weeks prior to the beginning of the study drug 
administration. 
7) If the screening test is within 14 days from the initial dose of a randomized controlled trial period, 
test on the cycle 1 day 1 is not required. 
8) Performed on cycle 4 day 1 in a randomized controlled trial period. 
9) If a long-term open trial period is to be begun within 2 weeks (except within 4 weeks in cases of 
chest/abdominal CT scan, nerve condition study, respiratory function test, and QOL survey) of the 
final dose of the study drug in a randomized controlled trial period (after 24 weeks or at the time of 
early transition), it does not have to be performed. 
10) Performed on day 1 in cycles 4, 7, and 10 of a long-term open trial period. 
11) Performed on day 1 in cycle 7 of a long-term open trial period. 
12) Prior to the beginning of a randomized controlled trial period, at the same time as obtaining 
consent for the trial, following confirmation of the level of understanding, consent on FPF300 safety 
control is obtained. In addition, prior to the beginning of a long-term open trial period, consent to the 
trial is obtained. 
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13) VEGF test is performed again even if it is within the acceptable range as cycle 1 day 1 is the 
baseline value. 
14) Prior to the drug administration, using the confirmation form for the FPF300 safety control 
compliance to confirm the patient’s compliance each time, and if there is no problem the drug may 
be administered. In addition, confirm the compliance with prohibited items by patients 4 weeks after 
the observation. 
 
Continuous administration test can begin the day after the final dose of the study drug in a 
long-term open trial period up to 8 weeks (continuation JPOST-12, beginning means the beginning 
of FPF300 administration). 
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25.4 Safety management compliance check of FPF300 
 
Safety management compliance check of FPF300 
 
Subject ID code:         year    month    day 
Please confirm patient compliance to the trial. Instruct the patient (or family members) to check the 
appropriate boxes in the form below with a pen.  
[A is for male patient, B is for female patient, and C is for both] 
Items to confirm Results 
① Do you understand how to use the sheet of 
pills?  
☐ Yes I understand. ☐ I am unclear. 
② Did you store this drug separately from 
other drugs and food in a designated 
location out of children’s reach? 
☐ Yes ☐ No  
③ Did you share, gift, or dispose of this drug?  ☐ Yes ☐ No  
④ Did you lose this drug? ☐ Yes ☐ No 
⑤ Did the drug administrator change? ☐ Yes ☐ No 
[A: male patients only] 
Items to confirm  Results 
⑥ Did you have a sexual intercourse with a 
pregnant woman? 
☐ Yes ☐ No 
⑦ Did you have a sexual intercourse without a 
condom? 
☐ I had no sexual intercourse 
☐ I had protected sexual intercourse 
☐ I had unprotected sexual intercourse 
⑧ Did your partner become pregnant? ☐ Yes ☐ No  
⑨ Did you provide sperm and semen? ☐ Yes ☐ No  
[C: female patients only] 
Items to confirm  Results 
⑩ Did you have a sexual intercourse? Did 
you use a defined contraceptive method?  
☐ I did not have sexual intercourse 
☐ I had protected sexual intercourse 
☐ I had unprotected sexual intercourse 
⑪ Did you lactate? ☐ Yes ☐ No 
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1. Principal Investigators and Study Sites 
No. Investigating institution Department  Investigator Title Address Phone No. 
1 
Hokkaido University 
Hospital 
Neurology Ichiro Yabe Assoc. 
prof. 
5 Chome Kita 14 Jonishi, Kita-ku, 
Sapporo-shi, Hokkaido, Japan 
060-8648  
011-716-1161
(switchboard) 
2 Chiba University Hospital Neurology Satoshi 
Kuwabara 
Prof. 1-8-1 Inohana, Chuo-ku, 
Chiba-shi, Chiba-ken, 
Japan  260-8677 
043-222-7171 
(switchboard) 
3 Niigata University Medical 
& Dental Hospital 
Brain Lab, 
Neurology 
Masatoyo 
Nishizawa 
Prof. 754 Asahimachidori 1 Bancho, 
Chuo-ku, Niigata-shi, 
Niigata-ken, Japan 951-8520 
025-223-6161 
(switchboard) 
4 Kindai University Hospital Neurology  Susumu 
Kusunoki 
Prof. 377-2 Onohigashi, 
Osakasayama-shi, Osaka-fu, 
Japan 589-8511 
072-366-0221 
(switchboard) 
5 Kagoshima University 
Medical and Dental Hospital 
Cranial 
Nerve 
Center, 
Neurology 
Osamu 
Watanabe 
Lecturer 8-35-1 Sakuragaoka, 
Kagoshima-shi, Kagoshima-ken, 
Japan 890-8520 
 
099-275-5111
(main 
switchboard) 
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2. Trial Coordinating Investigator Committee 
Prof. Satoshi Kuwabara (representative), Chiba University Hospital Department of Neurology 
Lecturer Sonoko, Misawa Chiba University Hospital Department of Neurology 
Prof. Hideki Hanaoka, Chiba University Hospital Clinical Trial Department 
1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba-ken, Japan 260-8677  
Tel: 043-222-7171 
 
3. Trial Coordinating Management Office 
Chiba University Hospital, Clinical Trial Department Prof. Hideki Hanaoka (person in charge) 
Chiba University Hospital, Department of Neurology Assistant Prof. Yukari Sekiguchi 
Chiba University Hospital, Department of Neurology Assistant Prof. Satsuki Mitsuma 
Chiba University Hospital, Department of Neurology Medical Staff Yuta Iwai 
Chiba University Hospital, Department of Neurology Medical Staff Keisuke Watanabe 
Chiba University Hospital, Department of Neurology Medical Staff Hiroshi Amino 
Chiba University Hospital, Clinical Trial Department Kanako Katayama 
Chiba University Hospital, Clinical Trial Department Reiko Aogi 
Chiba University Hospital, Clinical Trial Department Nanae Tanemura 
Chiba University Hospital, Clinical Trial Department Maharu Okubo 
1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba-ken, Japan  
260-8677  
   Tel.: 043-222-7171 
 
4. Study Drug Provider 
Fujimoto Pharmaceutical Corp. 
1-3-40 Nishiotsuka, Matsubara, Osaka Prefecture, Japan 580-0011 
   Tel.: 072-332-5151, FAX: 072-334-0372 
 
5. Efficacy and Safety Assessment Committee 
 Chiba University Hospital, Department of Respiratory Medicine Prof. Koichiro Tatsumi 
Yoshino Neurology Clinic       Clinic Director: Hide Yoshino 
Chiba University Hospital, Department of Dermatology  Prof. Hiroyuki Matsue 
  Chiba University Hospital, Department of Neurology   Associate Prof. Masahiro Mori 
 
6. Statistical Advisers  
Chiba University Graduate School of Medicine and School of Medicine,  
Course on Future Medical Global Therapeutic Research, Special Associate Prof. Yasunori Saito 
1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba-ken, Japan 260-8677  
Tel.: 043-222-7171 
 
90/92
Ver.2.9                                    JPOST-10 
3 
 
7. Project Support Organizations  
7.1 Contact Research Organizations（CROs) 
EPS Associates Co.  
EPS Associates Internal Project Supervisor: Tetsuro Uzuhashi 
Tsuruya Building 3F, Shimomiyabicho 2−23, Shinjuku-ku, Tokyo, Japan 162-0822  
Tel.: 03-3868-5268, Fax: 03-3868-5270 
 
7.1.1 Monitoring 
EPS Associates Co.  
Monitoring Supervisor: Tetsuo Uzuhashi 
Personnel in Charge of Monitoring: Shion Hashimoto, Kaichi Saito, Takahiro Namiki, Masami Fujino,  
Kazunari Shimizu, Anri Ichijima, Kenji Funaki 
Tsuruya Building 3F, Shimomiyabicho 2−23, Shinjuku-ku, Tokyo, Japan 162-0822  
Tel.: 03-3868-5268, Fax: 03-3868-5270 
 
7.1.2 Patient Registration Center 
EPS Associates Co.  
Patient Registration Supervisor: Yuriko Tabata 
Tsuruya Building 3F, Shimomiyabicho 2−23, Shinjuku-ku, Tokyo, Japan 162-0822  
Tel.: 03-3868-5253, Fax: 03-3868-5254 
 
7.1.3 Data Management 
EPS Associates Co.  
Data Management Supervisor: Junko Tashiro 
Tsuruya Building 3F, Shimomiyabicho 2−23, Shinjuku-ku, Tokyo, Japan 162-0822  
Tel.: 03-3868-7227, Fax: 03-3868-5188 
 
7.1.4 Statistical Analysis 
EPS Associates Co.  
Statistical Analysis Supervisor: Yoshikazu Yamabe  
Tsuruya Building 3F, Shimomiyabicho 2−23, Shinjuku-ku, Tokyo, Japan 162-0822  
Tel.: 03-3868-7227, Fax: 03-3868-5188 
 
7.1.5 Allocation Coordinator 
EPS Associates Co.  
Allocation Supervisor: Yuriko Tabata 
Tsuruya Building 3F, Shimomiyabicho 2−23, Shinjuku-ku, Tokyo, Japan 162-0822  
Tel.: 03-3868-5253, Fax: 03-3868-5254 
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7.2 Auditors 
Fujimoto Pharmaceutical Corp. Pharmaceutical Affairs Law Regulation Department 
Auditing Supervisor Fumiko Tsurita 
Personnel in Charge of Auditing: Kazuhiko Morimoto, Mayumi Horino, Ayumi Otsuki, Aya Takada, 
Takuya Hada, Mariko Yoshida, Mai Okada 
1-3-40 Nishiotsuka, Matsubara-shi, Osaka-fu, Japan 580-0011 
Tel.: 072-332-5151, Fax: 072-334-0372 
 
7.3 Central Laboratory (serum vascular endothelial growth factor, VEGF) 
EPS Associates Co.  
6-5-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan 163-1310 
Tel.: 03-5324-2601 (switchboard) 
 
7.4 Central Laboratory (serum free light chain, qualitative M protein, immunofixation) 
Chiba University Hospital, Examination Department 
1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba-ken, Japan  260-8677 
Tel.: 043-222-7171 
 
7.5 Central Laboratory (blood concentration measurements) 
Fujimoto Pharmaceutical Corp. 
1-3-40 Nishiotsuka, Matsubara-shi, Osaka-fu, Japan 580-0011 
Tel.: 072-337-7255, Fax: 072-337-8117 
 
8. Other Related Organizations 
Center for Clinical Trials, Japan Medical Association 
Bunkyo Green Court 17F, 2-28-10 Honkomagome, Bunkyo-ku, Tokyo, Japan 113-0021    
Tel.: 03-5319-3781, Fax: 03-5319-3790 
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